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ABSTRACT 
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Hydrodynamic delivery is a powerful tool that allows delivery of macromolecules 
to the kidney culminating in gene expression. This finding is important in the fight 
against kidney disease. Current therapy for kidney injury, specifically acute kidney 
injury, is lacking. Supportive care in the form of IV fluids and medications aimed at 
restoring Glomerular Filtration Rate (GFR) and urine output are currently used. However, 
even with these treatments, prognoses of patients diagnosed with this disease remains 
poor. We believe that hydrodynamic delivery provides a mechanism that can be used to 
reverse and prevent AKI. Hydrodynamic delivery following ischemic injuries leads to 
reductions in serum creatinine and infiltrating mononuclear cells, as well as increased 
renal blood flow and survival. These changes are due to reductions in vascular congestion 
and inflammation typically seen following injury. To determine the underlying 
mechanisms of gene delivery preventing AKI, we used candidate genes identified in a 
proteomic screen on kidneys that recovered from AKI. We selected Isocitrate 
Dehydrogenase II (IDH2) and Sulfotransferase 1C2 (SULT1C2) for study and found that 
delivery prior to injury prevents serum creatinine increase and reduces cell death. We 
found that gene delivery of IDH2 prevents a glycolytic shift typically seen following 
ischemic injuries. The mechanism underlying the prevention of this shift are seen in 
increased ATP stores and spare respiratory capacity allowing the cell to remain in an 
 
 
 
xvi 
oxidative state. Additionally, we show that SULT1C2 post-translationally modifies the 
mitochondria membrane, increasing oxidative phosphorylation providing the cell with 
additional energy needed in times of oxidative stress. These candidate genes allow cells 
to remain in an oxidative state preventing the activation of cell death pathways typically 
activated following injury, thereby preserving normal kidney function. 
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CHAPTER 1: INTRODUCTION 
1.1 The Kidney 
 
1.1.1 Why Study the Kidney 
The kidney is a dynamic organ. Its functions range from waste excretion to 
electrolyte balancing, to maintaining a hormone balance that is important for regulating 
blood pressure, contributing to red blood cell development, and aiding in bone formation 
and turnover (2-6). The kidney’s regulation is pivotal for human life. At rest, kidneys 
utilize >25% of cardiac output at any given moment and any slight change in that output 
has the potential to reduce kidney function leading to disease (2). Similarly, if urine 
output decreases, this is also an indication of kidney disease. It is important that the 
filtration of waste from the blood into the urine be maintained at constant and consistent 
rates to prevent kidney disease and diseases elsewhere. If homeostasis cannot be 
maintained, treatment may be required. The costs and the length of hospital stays for 
patients suffering from kidney injury, specifically acute kidney injury (AKI), are on the 
rise. Patients diagnosed with AKI not requiring dialysis spend an extra 7,900 dollars and 
stay three additional days in the hospital. Patients requiring dialysis spend an extra 
42,000 dollars and stay an extra twelve days (3). As of 2017, patients diagnosed with 
AKI accrue more in hospital costs then patients suffering from myocardial infarctions and 
gastrointestinal bleeding (2-4). Currently, patients hospitalized for kidney disease have 
one treatment option, renal replacement therapy (dialysis or transplant). Patients who are 
initially hospitalized with this disease category are supported with fluids and medications, 
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such as steroids or ionotropes, with the sole purpose of reestablishing normal glomerular 
filtration rates. Once diagnosed with kidney disease, patients are afflicted their entire life 
and progression from acute to chronic to end stage disease is likely. Novel therapies are 
needed for patients suffering not just from AKI but other forms of kidney disease in order 
to prevent additional increases in both cost of care and length of stay.  
  
1.1.2 Renal Physiology 
As mentioned previously, the kidney is involved in balancing electrolytes and 
hormones, regulating blood pressure, and excreting waste. These processes occur in the 
nephron. The nephron is composed of two major units, each of which serves specific and 
distinct functions. The first unit, the renal corpuscle, is composed of the glomerulus and 
Bowman’s Capsule. The second unit, known as the tubule unit, consists of proximal, 
distal, and connecting tubules in addition to the Loop of Henle (Fig 1)(7).  
The main role of the renal corpuscle and its components is filtration. The 
glomerulus is responsible for filtering blood, regulating filtrate pressure to ensure normal 
glomerular filtration rate, and controlling what is filtered from the blood. The glomerulus 
is made up of three units that work together to regulate filtration- filtrated endothelial 
cells, podocytes, and extracellular membrane. Together these three units work as a sieve, 
regulating the flow of water and small solutes while retaining proteins, sugars, and other 
electrolytes in the body (8-13). Damage to any one of these three components has the 
potential to cause kidney disease. 
The second unit of the nephron is the tubule unit. The main function of the tubule 
is filtrate and water reabsorption back into circulation (7). The proximal tubule, for 
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example, is involved in reabsorption of water, glucose, amino acids, Na+, Cl-, urea, and 
K+, among other ions. The loop of Henle is also important in water and sodium chloride 
reabsorption. The varying permeability in the loop regulates where (ascending or 
descending limb) and what (water or solutes) is reabsorbed into circulation. Once past the 
Loop of Henle, the filtrate passes through the distal tubule. The distal tubule is involved 
in Ca2+ reabsorption and regulation of urine pH. Once through the distal tubule, the 
filtrate collects in the collecting duct and then exits the body as urine (12-15). 
 
1.1.3 Renal Diseases Classification 
Renal diseases can be classified into three main categories and each has its own 
criteria. These three categories are Acute Kidney Injury (AKI), Chronic Kidney Disease 
(CKD), and End Stage Renal Disease (ESRD). AKI is defined as a sudden decrease in 
glomerular filtration rate and urine output coupled with increases in blood urea nitrogen 
and serum creatinine. To be diagnosed with AKI patients must present with a 1.5-2-fold 
increase in serum creatinine (SCr) or 50% reduction in GFR, or a urine output of <0.5 
mL/kg for twelve hours. CKD on the other hand is similar in presentation to AKI with the 
exception that patients present with deteriorating kidney function for periods greater than 
one month and typically higher SCr. Finally, ESRD is classified by complete renal failure 
for greater than three months and a dependence on dialysis for that time period. Once 
diagnosed with kidney disease, the progression from AKI to CKD to ESRD is likely. 
While current treatment methods are lacking, what is known is that AKI maybe reversible 
and a likely area for successful treatment (16-18). 
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1.2 Acute Kidney Injury (AKI) 
 
1.2.1 Establishing the Definition of AKI 
There is not a singularly agreed upon definition of AKI. The aspects of AKI that 
make it difficult to classify are the dynamic nature of the kidney and the patients that 
present with the disease. Essentially, clinicians refer to AKI as a rapid loss of kidney 
function with a simultaneous decrease in glomerular filtration and increases in serum 
creatinine and/or blood urea nitrogen (2, 19, 20). Clinicians established this definition of 
AKI during the Acute Dialysis Quality Initiative (ADQI) where they were able to lay the 
foundations for categorizing kidney injury. The criteria for these categories are laid out 
using the acronym RIFLE: Risk, Injury, Failure, Loss, and End stage renal disease and 
are used in determining various stages of kidney disease (Table 1) (17). These criteria 
have gone through modifications over the past decade and a half. The first was in 2005 
during the Acute Kidney Injury Network (AKIN) coalition meeting; this modification 
included patients that present with changes in kidney function, but fell below the initial 
risk category (Table 2) (17). In 2012, during Kidney Disease: Improving Global 
Outcomes meeting, it was established that changes made to the RIFLE criteria guidelines 
set up by ADQI and AKIN were successful in diagnosing patients with kidney injury all 
over the world (Table 3).  
 
1.2.2 Scope of Clinical Issues 
Acute Kidney Injury (AKI) present in 2-7% of hospitalized patients, but increases 
to over 15% for patients admitted to the ICU. Once hospitalized for AKI, mortality rates 
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increase to over 50% (2, 3). The critical issue with AKI is that there is no known cure; 
only supportive care can be provided. Even with supportive care, relapse is likely and 
progression to ESRD likely. Aside from the progression of AKI to CKD or ESRD, there 
are other complications that can arise from AKI such as metabolic acidosis, high 
potassium levels, uremia, and changes in fluid balance (2, 19, 21). The only treatment 
option following the progression of AKI is renal replacement therapy. Of the three 
mentioned kidney diseases AKI is the only type that is reversible. Recent findings have 
indicated that gene therapy may play a crucial role in reversing the progression of AKI 
(22).  
 
1.2.3 AKI: The Causes and Types 
Once diagnosed with Acute Kidney Injury, the next step is to determine the type 
of acute injury and the potential cause of that injury. AKI is divided into three etiologies: 
prerenal, renal, and postrenal. Prerenal, as the name describes, is an acute injury 
associated with changes outside the kidney prior to renal circulation. Prerenal injuries are 
associated with decreases in cardiac output of >25%. Causes of prerenal acute injury 
include hypovolemia from fluid loss, congestive heart failure, and decreases in vascular 
resistance due to sepsis or anaphylaxis to name a few.  
Renal acute injury entails injuries that occur directly to the kidney itself that can 
lead to damage to tubules, interstitium, vasculature, or glomeruli. This damage can result 
in acute tubular necrosis, glomerulonephritis, and acute interstitial nephritis.  
The final type of acute injury is caused by post renal injury, or changes in urine 
output. These changes in urinary output can be the result of prostate cancer or 
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inflammation, cervical cancer, catheter obstructions, kidney stones, or growths that cause 
changes in the bladder or urethra (2, 7, 23-26).  
 
1.2.4 Mechanisms of AKI 
Much like the definition of AKI, its causes are complex and diverse. Causes of 
AKI range from sepsis, to systemic inflammation, to an ischemic insult. The complexities 
of these causes are difficult to parse thus making determination of injury onset arduous. 
(Table 3) (7).  
Sepsis, an uncontrolled immune response to infection leading to organ failure, is 
the most common cause of AKI in critically ill patients and is diagnosed as the cause of 
AKI in 40-50% of these patients (27, 28). Causes of sepsis-induced-AKI include hypo-
perfusion, microvascular dysfunction, inflammation, and tubular epithelial cell 
reprogramming (differentiation into a new cell type or self–renewal). Septic AKI was 
once believed to be the result of changes in perfusion, mainly hypoperfusion. However, 
recent studies have indicated that even in the absence of abnormal flow, septic AKI can 
still occur. The models now point to changes in tubular cell behavior, cellular response to 
inflammatory cytokines, and endothelial communication as potential causes of septic 
AKI (29-36).  
Systemic inflammation is also a cause of AKI. Mechanistically, the inflammatory 
response is brought about during cellular reprograming in response to stress. In this case, 
the stressor can lead to apoptosis and necrosis. In the kidney, the cells most susceptible to 
stress are the tubular epithelial cells (37-41). During a necrotic event, the epithelial cells 
release damage associated molecular patterns, DAMPs, which lead to the activation of 
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pattern recognition receptors, such as Toll-like receptors or other inflammatory receptors 
(37-41). The activation of these receptors allows recruitment and activation of immune 
cells such as monocytes, dendritic cells, and macrophages that then release their 
chemokines. The release of chemokines such as CXCL1 or CXCL5 contributes to the 
activation of immune and inflammatory responses. To maintain a pro or anti-
inflammatory state requires specific pro or anti-inflammatory cytokines, and it is the 
balance between the two that regulates inflammation. During an ischemic event, the 
balance between the cytokine population changes allowing an accumulation of pro-
inflammatory cytokines, leading to inflammation. This inflammation causes changes in 
vascular permeability and blood flow (37-41). 
Another common model for AKI is an ischemic injury. During ischemic injury, 
renal blood flow decreases leading to decreased oxygen supply to the kidney and a 
buildup of waste products such as ureic nitrogen and creatinine. The buildup of these 
waste products and the lack of oxygen lead to reductions in both oxidative 
phosphorylation and ATP levels in the cell. As stated previously, reductions quickly lead 
to cellular reprogramming and apoptotic or necrotic cells. In the case of renal ischemia, 
the cell type that is most affected is the proximal tubular epithelial cell. ATP depletion in 
this cell type quickly leads to changes in cellular polarity and signaling, typically 
followed by cell death.  
 In addition to the epithelium, the endothelium and its cells are also critical in 
regulating AKI. As previously mentioned, changes in microcirculatory flow in the kidney 
lead to poor endothelial barrier function, the recruitment of inflammatory cells, and 
reductions in vasodilators (NO for example). Taken together, damage to the endothelium  
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Figure 1: Schematic Illustration of a Nephron (7). 1- Renal corpuscle consisting 
of Bowman’s capsule and the glomerulus; 2-Proximal Convoluted Tubule; 3-Proximal 
Straight Tubule; 4- Descending Thin Limb of the Loop of Henle; 5- Ascending Thin 
Limb of the Loop of Henle; 6- Think Ascending Limb of the Loop of Henle; 7- Macula 
Densa; 8- Distal Convoluted Tubule; 9- Connecting Tubule; 10- Cortical Collecting 
Duct; 11- Outer Medullary Collecting Duct; 12- Inner Medullary Collecting Duct. 
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can lead to cellular coagulation: reductions in vascular space leading to reductions in 
blood flow and culminating in ischemic injury (6, 8, 9, 42, 43). 
 
1.2.5 Managing AKI 
Currently the options for clinical management of AKI are limited. Patients 
admitted to the hospital are treated on a symptom-by-symptom basis. The goal of 
treatment is to reestablish homeostasis by restoring blood flow to the kidney and 
restoring a normal GFR. The care provided is supportive only. This is accomplished by 
providing fluids, electrolytes and controlling pH. If this fails, or if patients are suffering 
from a severe injury, renal replacement therapy is the only option. 
 
1.3 Ischemic Preconditioning (IPC) 
 
1.3.1 Background of IPC 
Ischemic preconditioning was first observed by Murry et al in 1986 (44). Since 
the original observation that applying non-lethal doses of ischemia to target organs can 
confer protection against subsequent injury, it has been thought that a full understanding 
of this phenomenon would offer an entree to therapy for ischemic injury. Following 
Murry et al’s demonstration of this phenomenon, studies were conducted on different 
organs such as the heart, brain, liver, and kidney to name a few (9, 44-47). The 
conclusions drawn from these studies were similar to what Murry et al demonstrated in 
1986, that ischemic episodes to these organs protected them from future injury. 
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Table 1: RIFLE Criteria for AKI Classification 
 
 
 
 
 
 
 
Risk
Loss
ESRD
Injury
Failure
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Table 2: AKIN Staging System for AKI from Murugan and Kellum (17). 
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Table 3: Potential Pathways Implicated in the Development of AKI.(7) 
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1.3.2 Mechanism of IPC  
While the exact mechanisms of IPC are not well understood, what is known is 
that non-lethal doses of ischemia can confer protection to the target organ. Studies 
conducted on IPC have also shown that IPC reduces apoptotic cell death, endothelial 
dysfunction, oxidative stress production and inflammation (48-52). Two possible 
pathways that are implicated in IPC and its protective effects are the RISK, Reperfusion 
Injury Salvage Kinase, and SAFE, Survivor Activating Factor Enhancer pathways.  
The RISK pathway relies on the activation of G-protein-coupled ligands and the 
pro-survival kinases AKT and ERK. The combination of these kinases prevents the 
activation of pro-apoptotic factors and prevents mitochondria Permeability Transition 
Pore (mPTP) opening promoting cell survival (Figure 2) (49). Studies have demonstrated 
that stimulation of this pathway prior to ischemia confers protection. 
          The second pathway, the survivor activating factor enhancer (SAFE) pathway, 
behaves similarly to the RISK pathway in that it promotes cellular survival (Figure 3) 
(53). Unlike the RISK pathway, the SAFE pathway is activated by Tumor Necrosis 
Factor alpha, TNFα, leading to the activation of the JAK-STAT pathway. The activation 
of the STATs, particularly STAT 3 leads to the activation of pro-survival and proteins 
such as BCL-2, and reductions in pro-apoptotic proteins such as Bad. There is also data 
that indicates STAT 3 may even regulate mitochondria activity through mitochondria 
connexin 43 which is involved in releasing stored biochemical energy such as ATP, GTP, 
and NAD(P)H during stress (53-56).  
The result of both pathways is cell survival. Both pathways have been implicated 
in promoting survival through the upregulation of anti-apoptotic genes and the 
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downregulation of pro-apoptotic genes in addition to regulating mitochondria activity. 
These areas are potential targets for therapies that mimic IPC to prevent cell and organ 
death.  
 
1.3.3 IPC in the Kidney 
Ischemic preconditioning in the kidney was first studied by Zager et al (57). This 
work laid the foundation for studying IPC in the kidney. Using this foundation, Joo et al. 
demonstrated that IPC consists of two protective windows (58). These protective 
windows consist of an acute window, which begins immediately following IPC and 
extends for several hours and a late window which begins around 24 hours and lasts up to 
several weeks following recovery from injury. Acute IPC may be mediated by 
mechanisms related to ion channels and cell signaling such as the RISK and SAFE 
signaling pathways (48, 49, 53, 55, 59, 60). The late phase involves transcriptional 
activation and translation of cytoprotective proteins such as hypoxia induced transcription 
factors or heat shock proteins. Because mitochondria impairment represents an early step 
in the pathogenesis of renal injury, IPC may be mediated in part by preserving 
mitochondria function in response to IRI by preserving cellular ATP levels, reducing 
ROS production and inhibiting cell death pathways (60-62). 	
1.3.4 Involvement of Mitochondria in IPC 
Mitochondria involvement in ischemic preconditioning was first noted by Murry 
et al in 1986 and further analyzed in 1989. Murry and colleagues hypothesized two 
possible biochemical scenarios that led to ischemic injury, metabolite loss or catabolite 
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accumulation (63). Both of these biochemical processes focus on mitochondria and its 
involvement in IPC. They concluded that mitochondria protect cells from ischemia by 
conserving ATP and reducing the catabolite accumulation responsible for ischemic cell 
death. Future study conducted by other investigators revealed that Murry’s conclusions 
laid the foundation for the involvement of mitochondria proteins and signaling as 
regulators in IPC and therefore potential targets for therapy. To determine the 
mitochondria enzymes involved in IPC we conducted a proteomic analysis to determine 
protein targets for potential therapeutic use. One such protein, Isocitrate Dehydrogenase 
II (IDH2) is involved in the citric acid cycle and reactive oxygen species reduction and 
was upregulated during IPC. IDH2 was shown to mimic the effects of IPC when 
delivered to the rodent kidney.  
 
1.4 Mitochondria 
 
1.4.1 Structure 
Mitochondria are the powerhouse of the cell. These organelles are responsible for 
cellular energy production and regulation. To protect mitochondria and ensure normal 
function, they are surrounded by two membranes, an inner and outer membrane with 
different levels of permeability. The outer membrane contains protein pores and pumps, 
which regulate the flow of proteins, carbohydrates, ions, and other small molecules into 
mitochondria. The inner mitochondria membrane is less permeable than the outer 
membrane, as it is primarily responsible for housing the components of the electron 
transport chain (ETC). As a result, this membrane closely regulates the flow of ions from 
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the inner membrane space into the mitochondria matrix. The inner membrane folds into 
units called cristae to increase surface area to allow maximal ATP generation.  
The final component of mitochondria is the mitochondria matrix. This matrix is found 
inside the inner membrane and is the location of the citric acid cycle (TCA) its 
constituents (Fig 4).  
The combination of these mitochondria components allows for the establishment of 
the chemiosmotic mechanism. The mechanism relies on a closed system (membranes) to 
allow the flow of electrons down an electrochemical gradient to generate the energy 
needed to form ATP (64-66).  
 
1.4.2 Bioenergetics  
The generation of energy in the form of ATP or GTP in the mitochondria relies on the 
formation of reduction equivalents, NAD(P)H and FADH2. The formation of these 
molecules drives the generation of ATP by substrate level phosphorylation, also known 
as phosphate group transfer. The formation of NADH and FADH2 occurs during the TCA 
and their energy is used by the ETC to generate ATP. While these are not the only 
pathways that are regulated by mitochondria they will be the focus of this investigation. 
Previously mentioned, a major source of reduction potential is generated by the TCA. 
The cycle uses substrates generated from beta-oxidation and glycolysis via Pyruvate 
Dehydrogenase. During beta-oxidation, fatty acids are broken down by enzymes to form 
acetyl-coA which then enters the citric acid cycle. 
Glycolysis, through various enzymatic steps, converts a glucose molecule into two 
pyruvate molecules. These molecules then undergo oxidative decarboxylation carried out 
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by pyruvate dehydrogenase to generate acetyl- coA, which then enters the TCA. The 
TCA cycle (Figure 5) consists of eight steps that lead to the generation of 1 GTP, 3 
NADH molecules, and 1 FADH2 molecule per molecule of acetyl-coA.  
The four major dehydrogenases: Isocitrate, alpha-Ketogluterate, Succinate, and 
Malate Dehydrogenase are responsible for the generation of the NADH and FADH2 that 
feed into the ETC. Of these four enzymes, it is Succinate Dehydrogenase that forms the 
sole FADH2 molecule. In addition to the generation of NADH and FADH2, GTP is 
generated by substrate level phosphorylation during the conversion of Succinyl CoA to 
Succinate by Succinyl CoA Synthetase. The reduction potential generated from the TCA 
is then passed into the ETC (65, 66). Succinyl CoA Synthetase. The reduction potential 
generated from the TCA is then passed into the ETC (65, 66).  
The ETC consists of five major components (Figure 6). NADH and FADH2 carry 
electrons from the TCA cycle into the ETC. The electrons from NADH are carried into 
Complex I, NADH:Ubiquinone Oxidoreductase, while the electrons from FADH2 are 
carried into Complex II, Succinate Dehydrogenase by Succinate. From these complexes, 
the electrons are transferred by Ubiquinone to Complex III, Cytochrome bc1. From 
Complex III, the electrons are carried by Cytochrome c to Complex IV, Cytochrome 
Oxidase. The final electron acceptor is Oxygen, which is reduced to water upon receiving 
the electrons from Complex IV. As mentioned previously, the flow of electrons down a 
gradient is called chemiosmosis. The flow of electrons is governed by the reduction 
potential of the carrier and recipient molecules. Electrons flow from low reduction 
potential to high reduction potential and each component in the ETC has a higher  
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Figure 2: Reperfusion Injury Salvage Kinase (RISK) Pathway (49). 
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Figure 3: Survivor Activating Factor Enhancer (SAFE) Pathway (53). 
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reduction potential then the previous, thus allowing electron(s) to move from one 
component to the next. Coupled with the flow of electrons is the pumping of protons into 
the inner membrane space by Complexes I, III, and IV. Complex II, succinate 
dehydrogenase, is not a proton pump, and as a result electrons that initiate the chain at 
this complex generate fewer protons and thus less ATP than NADH. The protons from 
the inner membrane space then cycle through a proton channel in complex V, F1Fo ATP 
Synthase, which drives the formation of ATP (65, 66).  
Mitochondria membranes are dynamic and fluid. The proteins and lipids that 
make up each membrane are constantly being turned over. Damage to the mitochondria 
membrane may alter membrane potential and thus the ability to produce ATP, leading to 
the activation of cell death cascades (67). For this reason, it is important to study methods 
that can alter membrane potential in order to understand how to target mitochondria for 
potential treatments.  
 
1.4.3 Mitochondria and Disease  
Mitochondria are critically important regulators of cell homeostasis. Cells lacking 
mitochondria or that contain mitochondria where the amount of mutated DNA is greater 
than wild type DNA (mtDNA) initiate apoptotic pathways or succumb to necrosis due to 
poor ATP generation. For example, individuals with mutant Apolipoprotien L (APOL-1) 
have damaged mitochondria and are prone to cancer, renal disease and poor transplant 
reception (68-70). Cells with mitochondria that have alterations in permeability are also 
prone to cell death (67). Two qualities of mitochondria critical to understanding disease 
pathology are their maternal inheritance and that they contain their own genome (71-73). 
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Figure 4: Mitochondria Structure (64) 		
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Genes regulating mitochondria structure are predominately nuclear (roughly 900). 
However, the genes regulating respiration are encoded by mitochondria DNA. Damage 
to, or loss of these genes is associated with mitochondria disease. These diseases are 
typically associated with loss of normal electron transport chain structure and changes in 
respiratory capacity. These disease types tend to manifest in tissues that are highly 
aerobic such as: brain, skeletal muscle, and kidney (71, 74). Examples of diseases which 
effect brain and skeletal muscle include: MERRF, Myoclonic Epilepsy associated with 
Ragged Red Fibers, or MELAS, Mitochondrial Encephalomyopathy, Lactic Acidosis. 
Patients that present with these diseases suffer from seizures, muscle weakness, and 
infarctions and these symptoms are progressive. Similar to the brain and skeletal muscle, 
the kidney, and in particular proximal tubule epithelial cells, are highly aerobic and ATP 
dependent. De Toni-Debré-Fanconi syndrome, or proximal tubulopathy, occurs when 
sodium-potassium pumps fail due to low ATP levels. This disease is characterized by 
tubular proteinuria, glycosuria, hypercalciuria, and acidosis. In addition to tubulopathy, 
the glomerulus is also affected by mutated mtDNA. Patients with glomerular 
mitochondria defects present with glomerular lesions and sclerosis leading to poor 
glomerular filtration (74). Regardless of the disease type or organ affected, treatments for 
mitochondria disorders are lacking (71, 72, 74). A potential course of treatment would be 
to deliver the gene or genes that are missing to drive respiration and ATP generation. We 
show that hydrodynamic gene delivery to the kidney allows for the potential to treat these 
mitochondria diseases. 
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1.5 Isocitrate Dehydrogenase II and Sulfotransferase 1C2 
 
1.5.1 Isocitrate Dehydrogenase 
Isocitrate Dehydrogenases are a class of enzymes that catalyze the oxidative 
decarboxylation of isocitrate to alpha ketoglutarate. In humans and higher forms of 
eukaryotes this enzyme exists in three isoforms: IDH1, IDH2 and IDH3. Of the three 
isoforms only IDH3 reduces NAD+ and is found mainly in the mitochondria matrix and 
is a key regulator of the TCA cycle. IDH1 and 2 reduce NADP+ and play prominent roles 
in lipid metabolism, glucose sensing, reactive oxygen species (ROS) regulation and 
oxidative respiration (75-80).  
 IDH1 contains signaling sequences that target this particular isoform to the 
peroxisome where it functions in ROS regulation and oxidative mechanisms such as beta-
oxidation. Studies have indicated that IDH1 is found in particularly high levels in the 
liver. IDH2, on the other hand, contains signaling sequences that target it to 
mitochondria, and is involved in oxidative phosphorylation and glucose sensing. This 
isoform is found in high levels in lymphocytes, heart, and skeletal muscle. Of particular 
interest is the role IDH2 plays in response to cellular stress. Due to its localization in the 
mitochondria, IDH2 has been found to function in ROS regulation and the reduction of 
glutathione. Glutathione reduction is critical in the reduction of H2O2 to water. Studies 
have indicated that loss of IDH2 activity leads to increases in oxidative DNA damage, 
peroxide generation, and increases in cell death (81-85). 
Proteomic analysis of mitochondria lysates following IPC has implicated IDH2 as 
an activator of recovery pathways following injury. Han et al demonstrates that loss of 
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Figure 5: The Citric Acid Cycle (65) 
 
 
 
 
 
25 
 
 
 
 
 
 
 			
	
Figure 6: The Electron Transport Chain(65) 	
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IDH2 exacerbates the disease state and detail the importance of IDH2 in these recovery 
pathways (86). Of importance now is to determine the exact mechanism(s) of action so 
IDH2 may be used as a therapeutic agent to treat ischemic diseases. 
 
1.5.2 Structure and Function 
Isocitrate Dehydrogenase is a class of enzyme that carries out a critical step in the 
TCA. Specifically, IDH is responsible for the conversion of isocitrate into alpha-
ketoglutarate (Figure 7) (75, 87). The function of this enzyme is highly dependent upon 
the cofactor Mg2+. Studies show that in the absence of Mg2+ the structural changes needed 
for the catalytic activity of the enzyme do not occur and the enzyme fails to function 
properly (75). Aside from the substrate output, IDH is responsible for the production of 
key electron carriers necessary for the electron transport chain, ATP production, fatty 
acid synthesis, and alleviation of ROS. These enzymes can reduce either NAD+ to NADH 
or NADP+ to NAD(P)H. Isocitrate dehydrogenases are found both in mitochondria and 
the cytosol and the enzymes found in the mitochondria reduce either cofactor (88).  
 
1.5.3 IDH2’s Role in IPC 
As previously mentioned, IPC is the application of non-lethal doses of ischemia to 
a target organ to protect that organ from more significant ischemic episodes. In the 
kidney, the application of these non-lethal doses of ischemia has proven to protect the 
kidney from future ischemic events. While the exact mechanism of IPC is unclear, one 
possible mechanism of protection entails changes to mitochondria or cytosolic protein 
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expression. Mitochondria protein lysates were analyzed by Liquid Chromatography-Mass 
Spectroscopy (LC/MS) two weeks following IPC. To ensure that these animals did in fact 
receive an ischemic injury, serum creatinine measurements were taken pre- and post-
injury. As a normal byproduct of muscular metabolism, and a compound that is easily 
excreted by the kidney, serum creatinine is the gold standard for measuring changes in 
kidney function. The proteomic analysis carried out by Drs. Witzmann, Basile, and 
Bacallao indicated unique changes in the mitochondria proteome (Table 4). The protein 
most over expressed in preconditioned kidneys, sulfotransferase 1C2, is a cytosolic 
protein; its presence in the mitochondria proteome reflects the nature of the mitochondria 
isolation which aimed for preserving mitochondria function instead of a pure 
mitochondria isolation preparation. IDH2 is the second most over expressed protein 
(Table 4) and due to its function in the TCA cycle and as a branch point enzyme for 
precursor production, we chose this protein for further study.  
 
1.5.4 Sulfotransferase 1C2 (SULT1C2) 
Sulfotransferases are a class of enzymes that add sulfate groups to various targets 
resulting in activation of detoxification pathways of various molecules. These 
detoxification pathways lead to formation of water soluble compounds that are then 
excreted by the kidneys. Three families of sulfotransferases have been identified in 
humans: SULT1, SULT2, and SULT4. These families then fall into two groups: 
membrane bound and cytosolic (89-91). The membrane bound sulfotransferases are 
found in the Golgi, and are responsible for adding sulfate groups to proteins, lipids, and 
glycosaminoglycans. The addition of the sulfate group to these molecules leads to 
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changes in structure and function. The second group, the cytosolic group, is responsible 
for the metabolism of xenobiotics and other compounds such as steroids and 
neurotransmitters (89-91). SULT1C2 is a cytosolic sulfotransferase that is located in the 
kidney, liver, and stomach. Currently, the physiological role of SULT1C2 is unknown 
(92). We report here that SULT1C2, while found in the cytosol, is a critical component of 
mitochondria recovery from IRI (Chapter 5). 
 
1.6 Delivering Genes to the Kidney 
 
1.6.1 Choosing the Vector  
When first conceived, the idea of gene therapy was to replace mutant or defective 
genes. This idea first originated in the late 1960s and early 1970s. It was not until the 
early 1990s that the first human clinical trial was conducted. This trial involved the 
replacement of a key enzyme, adenosine deaminase, to control proper regulation of the 
immune system (93, 94). The absence of this gene proves fatal. The results of this first 
clinical trial proved successful and the idea of gene therapy expanded from that point. A 
key dilemma in gene therapy is determining how to deliver the gene of interest. Currently 
two models of gene delivery exist: viral and non-viral delivery. When determining the 
viral route to use, it is important to consider what criteria make an ideal vector. The six 
criteria include: high concentration to allow many cells to be infected, convenience and 
reproducibility of production, ability to integrate in a site-specific location or to be 
maintained at that location, a transcriptional unit that can be regulated by regulatory 
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elements, the ability to target to a particular cell type, and avoidance of an immune 
response (93, 94).  
 
1.6.2 Non-viral Vectors 
In the case of non-viral delivery, DNA is paired with cationic lipids, 
polysaccharides or polypeptides that help DNA pass through the cell membrane. Issues 
that arise with the use of non-viral vectors include poor transfection efficiency and 
potential toxicity. In order to increase the transfection efficiency of non-viral delivery, 
dosage was increased, but this leads to cellular toxicity. To combat the toxicity and 
immune stimulation issues, models have been designed that allow conjugation of the 
DNA to PEI or PEG (polyethylenimine/polyethylene glycol) polyplexes or lipoplex (95-
100). The formation of these complexes occurs due to positively charged lipids or 
polymers associating with negatively charged DNA. The benefits of forming these DNA 
polymer complexes include: preventing serum inactivation and enzymatic degradation of 
the DNA, and allowing the complex to enter the cell and the nucleus (95-97, 101-105). 
  
1.6.3 Viral Vectors 
Viral vectors are classified into 5 categories: retroviruses, lentiviruses, 
adenoviruses, adeno-associated viruses, and herpes simplex-1virus. Retroviruses are a 
group of viruses that utilize RNA as their gene delivery vector and integrate into their 
host genome. These viruses depend on their RNA genome being converted into DNA  
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Figure 7: Schematic Depicting the Conversion of Isocitrate into alpha-Ketoglutarate. The 
conversion of Isocitrate into alpha-Ketoglutarate is an important step in the Citric Acid 
Cycle. Two important cofactors play a role in the generation of alpha-Ketoglutarate, 
Mg2+ and NADP+. 
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upon entry into the cell. In order to accomplish this delivery, these viruses are composed 
of Gag, Pol, Env, and LTRs genes that are critical for integration into the host cell 
genome. This virus also depends on the packaging sequence (y) for its viral RNA to be 
distinguishable from cellular RNA. Advantages of retroviral vectors include a high 
efficiency of gene transfer into dividing cells and their ability to transfer genes precisely. 
Limitations with the use of retroviral vectors include failure to infect non-dividing cells 
and insertional mutagenesis leading to the activation of oncogenes. These viruses cannot 
be synthetically made. They must be cultured in cells for propagation, and due to their 
nature of integrating into dividing cells, these viruses can be gradually silenced over time 
(93, 94, 106, 107). Lentiviruses are a unique form of retroviruses which have the ability 
to infect dividing or non-dividing cells. A prime example of a lentivirus is HIV. The 
genome of a lentivirus includes accessory proteins, which allow its entry into either a 
dividing or non-dividing cell. Unlike other retroviruses, lentiviruses are not subjected to 
silencing which allows gene expression to continue for extended periods of time. 
Instances of six months of gene expression have been reported (93, 94, 107-109).  
The next groups of viruses are adeno and adeno-associated viruses. Unlike 
retroviruses, they do not integrate into their host genome and can infect either dividing or 
non-dividing cells. Since these viruses do not integrate into the host genome, their 
replication occurs as episomal replication in the cell nucleus, dependent upon cellular 
replication machinery. For gene transfer, the E1 gene, which is essential for viral 
replication, is replaced with the gene of interest and an enhancer-promoter element. This 
reduces the possibility for wild-type reversion and viral propagation. Advantages of this 
vector type include: higher titer  
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Table 4: Mitochondria Proteomic Analysis 
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volumes (>1011), the ability to carry large segments of DNA, and the ability to infect 
either dividing or non-dividing cells. Disadvantages of using adenoviruses include: 
stimulating an immune response and very limited expression time due to lack of 
chromosomal integration (93, 94, 107, 110). Adeno-associated viruses eliminate the issue 
of an immune response typically seen with adenoviruses. This virus is relatively simple. 
It is composed of a single strand of DNA, a cap gene which encodes the coat protein, and 
rep gene for replication and cell integration. Disadvantages of this vector are that it 
requires additional viral genes to aid in its replication and unlike adenoviruses, the adeno-
associated virus cannot be propagated directly from cells. Although viral titer levels are 
similar to adenoviruses, only a small number of particles are infectious (94, 111, 112).  
 
1.6.4 Non-viral Delivery Techniques 
The difficulty with non-viral gene delivery is that in the absence of the viral 
mechanisms which enable host infection, non-viral DNA has difficulty gaining access to 
the cell. In order to gain access to the cellular genome, methods have been established 
that allow passage through both the cell and nuclear membranes allowing access to DNA. 
Methods that have been developed include electroporation/stimulation, gene gun, 
ultrasound-facilitated transfer, and hydrodynamic delivery (113-117).  
Electrical stimulation of the cell membrane is thought to change the membrane 
permeability barrier, allowing the entry of plasmid DNA. While the exact mechanism is 
not known, it is hypothesized that electrical stimulation leads to formation of 
hydrophobic pores. After formation of the pores the plasmid moves down an 
electrochemical gradient and into the cell. Studies of electrically stimulated gene uptake 
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have been conducted in the skin, kidney, liver, lung, and different muscle types. While 
these studies seem promising, the major drawback of this technique is the damage to 
tissues and cells associated with applying an electrical shock and subsequent thermal 
heating. Additional limitations to this technique include a limited transfection area, and it 
is invasive. This damage leads to decreased transfection efficiency (118-120).  
Yang et al established gene expression with the gene gun in the late 1980s (121, 
122). The principle behind this technique involves DNA attached to gold particles being 
shot from a highly-pressurized gun with the momentum from gold particles driving 
penetration into cells or tissue. While gene expression has been reported, the highly 
pressurized direct onslaught of the cell or tissue surface leads to membrane damage, 
decreased gene expression, and potentially cell death (121, 122). 
Other techniques for gene delivery include direct intramuscular injection. Wolff et 
al demonstrated this method is possible and they show gene expression for two months 
(116). However, the ability to recapitulate this work has proven difficult and those that 
have accomplished this feat report only localized gene expression (116). Another 
technique that utilized direct injection is the micropuncture technique. The micropuncture 
technique was established in the 1920s by Wearn and Richards and successfully 
conducted in the kidney in 1941 by Walker et al (123, 124). Still used today, 
micropuncture allows the direct injection of compounds in various compartments in 
tissue. In kidneys, for example, direct injection of various fluorescent proteins (either 
viral or non-viral) has been successful and gene expression has been reported in the 
proximal tubule and even the glomerulus (Figure 8). While gene delivery with this 
technique has been successful, the gene expression is localized to the injection site and 
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widespread expression has not been observed (125, 126). The importance of widespread 
expression is critical for the treatment of disease.  
 
1.6.5 Hydrodynamic Fluid Delivery 
Hydrodynamic delivery is a process that uses pressure as a means to overcome 
internal permeability barriers to gene uptake. The force of injection leads to an increase 
in intravascular pressure, which causes changes in membrane permeability due to cellular 
stretching, which leads to gene uptake. First characterized in the 1990s, hydrodynamic 
delivery has been carried out in the heart, skeletal muscle, liver, diaphragm, and the 
kidney. The process was first carried out via the tail vein and from the tail vein followed 
by the limb vein. These delivery models report expression levels around 40% (127-132). 
Issues with renal fluid delivery arise from the glomerular filtration barrier (GFB) 
and its propensity to filter compounds out in the urine leading to low efficiency of gene 
expression. The direct target of renal hydrodynamic delivery is the proximal tubule 
epithelial cell due to its capacity to readily endocytose exogenous compounds. As 
previously mentioned, the limitation is the GFB. To avoid the limitations of the GFB, 
hydrodynamic delivery in the kidney has been attempted in the renal vein, artery, and 
ureter (22, 133). The current model established by Dr. Peter Corridon is renal vein 
injection (Figure 9) (22). Studies of hydrodynamic fluid injection through the renal vein 
have indicated high levels of gene expression from either viral or non-viral vectors 
(Figure 10) (22). Our studies indicate that injection forces between 60-75 mmHg are 
required for tubular uptake and gene expression (Figure 11). The utilization of this 
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technique is the driving force for the treatment of renal injury, both before and after 
disease onset.  
To better understand the mechanisms of hydrodynamic delivery in the kidney, we 
set out to study its mechanism of action following an Ischemia Reperfusion Injury (IRI) 
(Chapter 3). Using our proteomic data, we determined that delivering IDH2 or SULT1C2 
by hydrodynamic delivery has the potential to prevent AKI. We next studied if gene 
delivery prior to IRI is protective and if so, determine the mechanism of protection 
(Chapter 4).  
 
1.7 Studies of Renal Function 
Hydrodynamic isotonic fluid delivery (HIFD) to the kidney has the potential to 
ameliorate AKI (Chapter 3). To ensure normal kidney physiology, images and injury 
scoring of the kidney were conducted using light microscopy, confocal or 2-photon 
imaging, and tissue sectioning with staining. SCr measurements were analyzed to ensure 
amelioration of the disease and Florescence Activated Cell Sorting (FACS) was 
conducted to determine changes in immune response. As mentioned previously, AKI 
leads to changes in renal blood flow and even changes in cellular permeability.  
2-photon imaging and line scans allowed us analyze changes in permeability and blood 
flow. The capitulation of this data leads us to believe that HIFD has the potential to 
ameliorate AKI (1).  
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1.8 Studies of Mitochondria Function 
Hydrodynamic delivery of IDH2 or SULT1C2 has the potential to prevent AKI 
mimicking IPC (Chapter 4 and 5). IDH2 localizes to and alters the activity of the 
mitochondria. Following hydrodynamic delivery, we imaged mitochondria to ensure 
normal mitochondria physiology. Once normal physiology was established, we set out to 
analyze respiration, ATP levels, membrane potential and reduction potential. The 
culmination of our in vivo and in vitro studies indicates that IDH2 has the potential to 
mimic late window ischemic preconditioning. Hydrodynamic delivery of SULT1C2 post-
transitionally modifies the mitochondria leading to increases in membrane potential and 
oxidative phosphorylation protecting the cell from oxidative stress. 
 
1.9 Hypothesis 
Hydrodynamic Isotonic Fluid Delivery (HIFD) is a means to ameliorate AKI. 
Hydrodynamic fluid delivery following AKI increases blood flow and membrane 
permeability compared to sham IPC alone, allowing for small molecule uptake. This 
delivery is also shown to improve renal injury scoring, reduce SCr levels, and reduce 
inflammation and the inflammatory response within the kidney. This data demonstrates a 
possible mechanism for hydrodynamic isotonic fluid delivery and the ability to translate 
this method to the bedside.  
For patients that are at increased risk for AKI, hydrodynamic delivery of 
candidate genes shows the potential to prevent AKI by mimicking late window ischemic 
preconditioning. Gene delivery of IDH2 reduces cell death and SCr 
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Figure 8: Micropuncture Gene Delivery to the Kidney (126). The GFP expression 
is located in the injected proximal tubule. 
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levels and leads to increases in mitochondria membrane potential, oxidative 
phosphorylation, and ATP levels. The mechanism by which protection occurs is to 
prevent a Warburg (glycolytic) shift by increasing ATP reserves, spare respiratory 
capacity, and Complex II activity. The combination of hydrodynamic isotonic fluid 
delivery and gene therapy has the potential to be used in the clinic to treat AKI. The 
current therapeutic models are lacking and these translatable techniques have the 
potential to be powerful therapeutic treatments for AKI. 
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Figure 9: Renal Vein Hydrodynamic Delivery. The pressure generated by 
injection through the renal vein leads to gene uptake and expression in the kidney. 
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Figure 10: Hydrodynamic Fluid Delivery of EGFP from Corridon et al (22). 
Arrows indicate gene expression in proximal tubule as a result of gene delivery. Panels 
A/D are 2 photon images of tubular auto-fluorescence, while panels B/E show EGFP 
expression following gene delivery 
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Figure 11: Hydrodynamic Injection Pressure (1). The average of three 0.5 cc 
saline injections studies indicated that forces of 60-75mm Hg lead to gene expression 
within the kidney.  
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CHAPTER 2: MATERIALS AND METHODS 
2.1 Materials 
All fluorescent probes were purchased from ThermoFisher Scientific (Waltham, 
MA). IDH2 antibody was purchased from Protein Tech (Chicago, IL). Sulfotyrosine 
antibody was purchased from MilliporeSigma (Billerica, MA). The c-MYC antibody 
(9e10), developed by JM Bishop at the University of California, San Francisco, was 
obtained from the Developmental Studies Hybridoma Bank, created by the NICHD of the 
NIH and maintained at The University of Iowa, Department of Biology, Iowa City, IA 
52242. Beta actin was purchased from MilliporeSigma (Billerica, MA). All secondary 
antibodies were purchased from Jackson Laboratories (West Grove, PA). All plasmid 
DNA was purchased from Origene (Rockville, MD). Human recombinant SULT1C2 was 
purchased form Abcam (Cambridge, MA). 3’ Phosphoadenosine-5’ Phosophosulfate 
(PAPS) was purchased from MiliporeSigma (Billerica, MA). Cholesterol Sulfate was 
purchased from Avanti Polar Lipids, inc (Alabaster, AL). Laurdan was purchased from 
ThermoFisher Scientific (Waltham, MA). FIJI was obtained from the NIH website 
(National Institutes of Health, Bethesda, MD).(134) Transfection reagents were 
purchased from ThermoFisher Scientific (Waltham, MA). Seahorse reagents and kits 
were purchased from Agilent (Santa Clara, CA). Oroboros and Oroboros related reagents 
were purchased from Oroboros Instruments (Innsbruck, Austria).  
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2.2 Animals and Cell Culture 
 
2.2.1 Live Rats 
Male Sprague-Dawley rats (Envigo, Indianapolis, IN) (250-350 g) were used for 
our in vivo studies. Rats had access to food and water and all experiments conducted 
followed NIH guidelines. Rats were randomly assigned to control or experimental 
groups. Approval from Indiana University School of Medicine Institutional Animal Care 
and Use Committee (IACUC) and Richard L. Roudebush Veterans Adminstration 
Medical Center Animal Care and Use Committee was gained prior to all in vivo studies.  	
2.2.2 Mouse Proximal Tubule S3 Cell Culture 
Murine S3 proximal tubule epithelial cells were cultured in modified essential 
media (50:50 HAM F-12: DMEM, with L-glutamine, HEPES, sodium selenite, sodium 
pyruvate, phenol red, and insulin) supplemented with 1% penicillin-streptomycin, 7% 
fetal bovine serum (FBS), and 4.1% sodium bicarbonate solution (Sigma-Aldrich 
Corporation, St. Louis, MO) and grown in a 37oC, 5% CO and 38% O2. 
 Validation of the cell line origin was performed by IDEXX BioResearch 
(Columbia, MO) and the cells have the following STR profile (MCA-4-2: 20.3; MCA-5-
5: 17, 18; MCA-6-4: 14; MCA-6-7: 12, MCA-9-2: 15; MCA-12-1: 16, 17; MCA-15-3: 
22.3; MCA-18-3: 17; MCA-X-1: 28) 
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2.2.3 Mouse Embryonic Fibroblast Cell Culture (NIH 3T3) 
NIH 3T3 (135) cells were purchased from American Type Culture Collection 
(Manassas, VA) and maintained in culture according to ATCC recommendations. Mouse 
embryonic fibroblasts were cultured in Dulbecco’s modified eagle minimum essential 
media (American Type Culture Collection, Manassas, VA) containing 10% fetal bovine 
serum (FBS) and 1% Penicillin-streptomycin solution (Sigma-Aldrich Corporation, St. 
Louis, MO) and grown in 37oC, 5% CO2 incubator.  
 
2.3 Live Animal Surgeries 
 
2.3.1 Hydrodynamic Fluid Delivery 
Male Sprague-Dawley rats were anesthetized by inhaled isoflurane (Webster 
Veterinary Supplies, Inc., Devens, MA), with 2 L/O2 per minute for the entirety of the 
procedure (approximately 30 minutes) and placed on a heating pad. Animal respiration, 
reflex response, color, and body temperature were monitored throughout the surgical 
procedure. Once the animal was fully anesthetized, the abdomen was shaved and 
sanitized with three alternating rounds of Betadine Surgical Scrub (Purdue Products L.P., 
Stamford, CT) and 70% ethanol treatments. An abdominal midline incision was made to 
locate the left renal pedicle. The renal pedicle was isolated with 3-0 silk. The pedicle was 
elevated with the silk to place one micro-serrefine cross clamp (Fine Science Tools, 
Foster City, CA) across the pedicle for a three minute period. Following clamp 
placement, the silk was elevated again to inject 0.5 ml of 0.9 % sterile saline, or 2-3 µg/ 
gram body weight of transgenes into the renal vein at a rate of 0.1 ml/s, using a 30 -gauge 
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needle. The needle was then removed, and a cotton swab was applied to the injection site 
for a minimum of 30 seconds to induce hemostasis. After the three-minute period, the 
clamp was removed. Once blood flow to the kidney was restored, the midline incision 
was closed and the animal was allowed to recover. Analgesia was given according to 
IACUC guidelines.  
 
2.3.2 Hydrodynamic Fluid Delivery: Pressure Testing 
Rats were anesthetized as previously described and underwent renal vein injection 
as previously mentioned. To measure the pressure of injection, an additional one inch 30 
-gauge needle was bent 90 degrees and connected to the injection needle distal to the 
syringe. The additional needle was connected to a force transducer and pressure readouts 
were taken as the liquid exited the injection needle. The needle was then removed, and a 
cotton swab was applied to the injection site for a minimum of 30 seconds to induce 
hemostasis. After the three-minute period, the clamp was removed. Once blood flow to 
the kidney was restored, the midline incision was closed and the animal was allowed to 
recover. Analgesia was given according to IACUC guidelines.  	
2.3.3 Tetramethylrhodamine Methyl Ester (TMRM) Jugular Vein Infusion 
Rats were anesthetized, prepared, and monitored as previously described. 
Following preparation, the jugular vein was exposed and isolated using 3-0 silk loops. 
The superior loop was tied off and clamped to elevate the jugular vein. PE-50 catheter 
tubing was then inserted through a minor incision made in the vein and the second silk 
loop was tied off to anchor the catheter in place. The catheter was connected to a 1 mL 
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syringe containing either saline or TMRM. The animals were then placed on an Olympus 
FV 1000 confocal microscope (Olympus Tokyo, Japan) as described by Dunn et al (136) 
for multiphoton imaging. Image J was used to calculate the mean TMRM intensity value 
for each group as described by Hall et al (133). 
 
2.3.4 Tail Vein Injections 
Anesthetized rats were placed on a heating pad to allow the tail vein to dilate. A 
25-gauge butterfly needle, attached to a syringe with biomarkers, was then inserted into 
the tail vein.  
 
2.3.5 Ischemia Reperfusion 
Rats were anesthetized with an intraperitoneal injection of ketamine (100mg/kg) + 
xylazine (10 mg/kg) + acepromazine (2.5 mg/kg) cocktail and placed on a heating pad to 
maintain core body temperature. Animals were monitored throughout the surgical 
procedure and prepared as previously described. An abdominal midline incision was 
made to locate both left and right kidney pedicles. First, the right pedicle was isolated, 
followed by the left; micro-serrefine clamps (Fine Science Tools, Foster City, CA) were 
placed on both the left and right pedicle for a period of 35 minutes to induce ischemia. 
During ischemia, the midline incision was closed temporarily to maintain core body 
temperature. Following the 35-minute period, the clamps were removed from the pedicles 
to restore blood flow, the midline incision was closed and the animal was allowed to 
recover. Analgesia was given according to IACUC guidelines.  
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2.3.6 Ischemia Reperfusion: Unilateral Nephrectomy with 35-minute Contralateral-
Cross Clamp 
Rats were anesthetized with an intraperitoneal injection of ketamine (100mg/kg) + 
xylazine (10 mg/kg) + acepromazine (2.5 mg/kg) cocktail and placed on a heating pad to 
maintain core body temperature. Animals were monitored throughout the surgical 
procedure and prepared as previously described. An abdominal midline incision was 
made to locate both left and right kidney pedicles. The right pedicle was isolated and tied 
off using 3-0 silk. Once the pedicle was ligated, the right kidney was removed and 
bleeding was monitored to ensure proper ligation. The contralateral kidney pedicle was 
clamped for 35 minutes. Following the 35-minute period, the clamps were removed from 
the pedicles to restore blood flow, the midline incision was closed, and the animal was 
allowed to recover. Analgesia was given according to IACUC guidelines.  
 
2.3.7 Ischemia Reperfusion Injury with 24-hour Hydrodynamic Isotonic Fluid 
Delivery 
Rats were anesthetized with an intraperitoneal injection of ketamine (100mg/kg) + 
xylazine (10 mg/kg) + acepromazine (2.5 mg/kg) cocktail and placed on a heating pad to 
maintain core body temperature. Animals were monitored throughout the surgical 
procedure and prepared as previously described. An abdominal midline incision was 
made to locate both left and right kidney pedicles. First, the right pedicle was isolated, 
followed by the left; micro-serrefine clamps (Fine Science Tools, Foster City, CA) were 
placed on both the left and right pedicle for a period of 35 minutes to induce ischemia. 
During ischemia, the midline incision was closed. Following the 35-minute period, the 
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clamps were removed from the pedicles to restore blood flow, the midline incision was 
closed and the animal was allowed to recover. Analgesia was given according to IACUC 
guidelines.  
24 hours later the following procedure was conducted. Male Sprague-Dawley rats 
were anesthetized by 130mg/cc thiobutabarbital (Inactin Hydrate). Animals were 
monitored throughout the surgical procedure and prepared as previously described. The 
renal pedicle was isolated with 3-0 silk. The pedicle was elevated with the silk to place 
one micro-serrefine cross clamp (Fine Science Tools, Foster City, CA) across the pedicle 
for a three-minute period. Following clamp placement, the silk was elevated again to 
inject 0.5 ml of 0.9 % sterile saline, or 2-3 ug/ gram body weight of transgenes into the 
renal vein at a rate of 0.1 ml/s, using a 30 -gauge needle. The needle was then removed, 
and a cotton swab was applied to the injection site for a minimum of 30 seconds to 
induce hemostasis. After the three-minute period, the clamp was removed. Once blood 
flow to the kidney was restored, the midline incision was closed. Following 
experimentation, animals were euthanized according to IUCAC guidelines. 
 
2.3.8 Intravital Imaging 
 
2.3.8.1 Surgery 
Rats were anesthetized with an intraperitoneal injection of 130 mg/kg of 
thiobutabarbital (Inactin Hydrate). Animal respiration, reflex response, color, and body 
temperature were monitored throughout the surgical procedure. Once the animal was 
fully anesthetized, the left flank was shaved and then the animal’s left kidney was 
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located. Following location, a small incision was made on the flank and the kidney was 
exposed through the incision. The animal was then transported to the imaging room for 
renal imaging (Figure 12).  
 
2.3.8.2 Confocal or 2-Photon Microscopy Setup 
The kidney was placed face down into a 35mm glass dish allowing the rat body 
weight to stabilize the interaction between the kidney and the stage to reduce motion 
(Figure 12). Saline was poured into the dish to ensure the kidney did not dry out. An 
Olympus FV 1000 MPE microscope (Olympus, Tokyo, Japan) with a Spectra Physics 
MaiTai Deep Sea Laser (710-990 nm) with a 20 or 60X water immersion objective was 
used for imaging. Intravital images were acquired using wavelengths ranging from 820-
860 nm. 
This system is also equipped with two external detectors for multi-photon 
imaging and dichroic mirrors to collect red, green, and blue light emissions. This light is 
collected via a three-band pass filter system. Blue light is collected between 420-460 nm, 
green light between 495-540 nm, and red light between 575-630 nm. For GFP studies, the 
pseudo green and red channel were merged to eliminate the possibility of tubule 
autofluorescence.  
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Figure 12: Intravital Imaging Preparation. (Courtesy of Ruben Sandoval) 
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2.3.8.3 Fluorescence Recovery After Photo-bleaching 
Four days prior to imaging male Sprague-Dawley rats (250-350g) received 
hydrodynamic delivery of adenoviral GFP occludin or occludin 860 as previously 
described. Animals were prepared for intravital light microscopy as previously described. 
For FRAP, GFP occludin images were acquired in multi photon mode and bleaching of 
the occludin protein occurred in one photon mode. Our FRAP studies followed the 
methods established by Zheng et al (137).  
 
2.3.8.3 Blood Flow Measurements 
24 hours following renal IRI, isoflurane-anesthetized rats were prepared for 
intravital light microscopy as described above. A line scan was generated from the center 
of the vessel of interest continuously at a rate of two milliseconds per line for one second 
(1000 total lines). The scan measures flowing red blood cells, which do not take up dye 
and are therefore black. To analyze the scan, all channels of the line scan are merged into 
a single channel. This results in a vertical axis denoting time and a horizontal axis 
denoting the length or distance of the scan. The velocity of the blood cells was 
determined using the dark lines which depict the movement of the blood cell along the 
scan over time. The flow velocity was determined by measuring the slope as described by 
Dunn et al (136).  
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2.3.8.4 Vascular Permeability Studies 
24 hours’ post-nephrectomy with contralateral ischemia reperfusion injury, 
hydrodynamic isotonic fluid delivery was performed on the remnant kidney. 20 minutes 
after hydrodynamic fluid isotonic delivery, 150 kDa TRITC conjugated dextran and 
Hoechst 33342 was injected via tail vein. Intravital imaging was performed on the kidney 
at a rate of two milliseconds per line for a total of five minutes. Vascular permeability 
was determined by measuring the change in red channel fluorescence along a line 
perpendicular to a capillary wall.  
Sequential changes in fluorescence intensity over time were used to determine the 
rate of high molecular weight dextran entry into the interstitial compartment. Ten fields 
were studied for each animal and statistical significance was determined at a p value less 
than 0.05 using Student’s t test.  
To evaluate changes in Hoechst 33342 signal, 512 x 512 image scans were 
collected with simultaneous acquisition of 420nm and 514nm wavelengths at one scan 
per second using 800nm excitation light in two-photon mode. Thirty scans were acquired 
from each animal with random field selection. Images were acquired 24 hours post-IRI 
and 20 minutes after hydrodynamic isotonic fluid delivery in post-IRI rats. Images were 
also collected from sham-operated rats. Image intensity values were obtained by defining 
a circular region of interest (ROI). Average intensity values were obtained by placing the 
ROI over nuclei in all cells in the field using FIJI (134).  
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2.4 Freeze Substitution and Embedding 
All samples were freeze substituted using a Leica Automatic Freeze Substitution 
(AFS) Unit (Leica Microsystems, Vienna, Austria). Samples were freeze substituted in 
0.01% OsO4, 0.1% GA, 0.25% uranyl acetate in acetone and embedded in LR Gold 
(Electron Microscopy Services, Hatfield, PA). The freeze substitution schedule was as 
follows: held at -90o C for three days, warmed to -25o C at 5o C per hour, then held at -
25o C for six hours. Some of the samples were warmed to 0o C over a 2.5 hour period, 
rinsed with 100% acetone, warmed to room temperature, infiltrated in 1:2 resin:acetone 
for two hours and then followed by 2:1 resin:acetone overnight. Samples were embedded 
and then polymerized at -20oC. Sections were cut with a Leica Ultracut UCT 
Ultramicrotome (Leica Microsystems, Vienna, Austria). Sections were imaged with a FEI 
electron microscope equipped with an AMT CCD camera.  
 
2.5 Evaluation of Renal Tubular Damage and RBC Congestion 
Renal tubular damage was evaluated from formalin-fixed paraffin embedded 
samples stained using hematoxylin and eosin (H&E). Six random images (three cortex, 
three outer medulla) were obtained using a Leica DMLB microscope (Scientific 
Instruments, Columbus, OH) using a 20x objective. For each kidney, an average of 60 
tubules were scored from images by an observer who was blinded to the treatments using 
a modified 1-4 scoring system described previously (138). Data presented are based on 
the average score per tubule corresponding to each animal. RBC congestion was analyzed 
using ImageJ software, whereby regions of interest were identified visually and used to 
calculate percent surface area (to determine vascular congestion).  
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2.6 Assessment of Renal Infiltrating Cells 
Harvested kidneys were minced and digested with liberase (2µg/ml; Roche, 
Basel, Switzerland) for 15 minutes at 37°C using Gentle MACs (Miltenyi, San Diego, 
CA). Digested tissue was filtered through a 100-µm filter mesh and washed with 
medium. Mononuclear cells were separated by Percoll (Sigma-Aldrich, St. Louis, MO) 
and counted by hemocytometer. To evaluate T lymphocytes, the cells were stained with 
antibodies against rat CD4 (PE-Cy7), CD8a (Alexa 647) and CD161 (PE-Cy7). To 
evaluate the T helper subtype, the cells were permeabilized and stained with antibodies 
against cytokines such as IFN-gamma (FITC; Th1), IL-4 (PE; Th2) and IL-17 (FITC; 
Th17). To evaluate regulatory T-cells, mononuclear cells were stained with either CD4 or 
CD4 along with Foxp3 (PE). To evaluate B cells and Mac/DC, mononuclear cells were 
stained with antibodies against RTIB (FITC) and Cd11b/c (PE) respectively. 
Fluorescence was measured using flow cytometry (FACSCalibur, BD Biosciences, San 
Jose, CA) and dot plots were analyzed using Flowjo software (Tree Star, Ashland, OR). 
Lymphocyte gating strategy was identical to that shown previously (139). The data is 
expressed as a total number of cells per gram of kidney. 
 
2.7 Serum Creatinine Measurements 
To determine the effectiveness of our plasmid in protecting renal mitochondria, 
serum creatinine measurements were collected prior to injury and 24-hours post injury. 
Animals were briefly anesthetized under isoflurane, and blood was collected via tail vein 
incision. Blood was collected in a heparin treated 1 mL Eppendorf tube. 
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Figure 13: Line Scan(1). Line scan info:24 hours following renal IRI, isoflurane-
anesthetized rats were prepared for intravital light microscopy as described above. 
A line scan was generated from the center of the vessel of interest continuously at a 
rate of 2 msec per line for 1 sec (1000 total lines). The scan measures flowing red 
blood cells, which do not take up dye, and are therefore black. To analyze the scan, 
all channels of the line scan are merged into a single channel. This results in a 
vertical axis denoting time and a horizontal axis denoting the length of the scan, or 
distance. The velocity of the blood cells was determined using the dark lines which 
depict the movement of the blood cell along the scan over time. 
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The tubes were then centrifuged at 10,000 x g for 10 minutes and the serum was stored at 
4oC. A Point Scientific QT 180 analyzer and creatinine reagent kit (Point Scientific, inc, 
Canton, MI) were used to analyze serum creatinine according to Point Scientific protocol. 
 
2.8 Proteomics 
Male Sprague-Dawley rats were subjected to an ischemia reperfusion injury as 
previously described. The animals were allowed to recover for two weeks. Following 
recovery, the renal mitochondria were isolated as previously described and frozen at  
-80oC until proteomic analysis. Proteomic analysis was conducted as described by 
Molloy et al (140, 141).  
 
2.9 Plasmid Vectors 
All plasmids were prepared using Qiagen Maxi prep systems (Qiagen, 
Chatsworth, CA, USA). These plasmids were suspended in saline for gene delivery and 
2-3 µg of DNA per gram body weight was delivered through the renal vein. The 
following plasmids were used: Mitochondria Isocitrate Dehydrogenase II (NADP+) 
(Origene Technologies, Inc., Rockville, MD), enhanced Green Fluorescent Protein 
(eGFP) Actin (eGFP-actin) and Tubulin (EGFP tubulin) (Clonetech Laboratories, Inc., 
Mountain View, CA). The mitochondria IDH2 is a nuclear encoded gene and an Open 
Reading Frame (ORF) clone of the Homo sapiens Isocitrate Dehydrogenase II. 
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2.10 DNA Gel Electrophoresis 
The E-Gel® with SYBR Safe 1.2% agarose gel (Invitrogen, G521801) was 
inserted into the E-Gel® PowerBaseTMv.4. Each well of the gel was loaded with 500ng 
plasmid DNA. The electrophoresis time was set at 30 min.  
 
2.11 Cellular Transfection 
2.0 x 105 cells were plated into each well of a six well plate the day before 
transfection (alternatively cells were plated and grown on a 35- mm glass bottom, No. 1.5 
coverslip dish with standard thickness of 0.17 mm (Corning Inc., Corning, NY)). 24 
hours later cells were transfected with either IDH2 or myc-IDH2 using Lipofectamine 
3000 kit, following the Lipofectamine 3000 transfection protocol (ThermoFisher, 
Waltham, Ma) and were collected for mitochondria respiration analysis, IHC, or confocal 
imaging 24-48 hours after transfection.  
 
2.12 Confocal or 2-photon Imaging of Fluorescent Cells 
Confocal imaging studies were conducted on an Olympus FV 1000-MPE 
Microscope (Olympus, Tokyo, Japan). Cell cultures were grown in 35mm glass bottom, 
No. 1.5 coverslip dishes with standard thickness of 0.17 millimeters (Corning Inc., 
Corning, NY) The dishes were placed above the objective and the microscope was set to 
acquire 512x512 pixels in blue, green, and red-pseudocolor images. To minimize both 
photoxicity and photobleaching, we reduced both the energy level of the excitation light 
and the duration of excitation.  
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2.13 Immunohistochemical Staining and Colocalization 
Immunohistochemical staining was conducted on myc-IDH2 and mock 
transfected NIH 3T3 using myc 9e10 antibody (1:100) and FITC donkey anti-rabbit as 
previously described (142). The cells were allowed to grow to 80% confluency on glass 
cover slips following transfection (48 hours). The cells were then fixed with 4% PFA for 
10 minutes and then washed with PBS three times. After fixation, the cells were 
permeabilized with 0.1% Triton X-100 (ThermoFisher Scientific, Waltham, MA) for 10 
minutes and then washed with PBS three times. After rinsing with PBS, the cells were 
blocked with 1% normal goat serum (ThermoFisher Scientific, Waltham, MA) in PBS for 
one hour at room temperature. Following blocking, the primary antibody solution was 
placed on the cells for 30 minutes at room temperature followed by two ten minute 
washes in PBS. Following the washing, a secondary antibody solution containing a 
1:20,000 dilution of Hoechst 33342, 100 nM Mitotracker Red, and secondary antibody 
was placed on the cells for 30 minutes. The cells were then washed in PBS as previously 
described. After the final rinse, the cells were mounted onto a slide using Fluorsave 
reagent (MilliporeSigma Billerica, MA) and allowed to dry overnight. Cells were imaged 
using an Olympus FV 1000 confocal microscope at 820 nm. Red to green colocalization 
indicated myc-tagged IDH2 localized to mitochondria. Manders colocalization tests were 
conducted as described by Dunn et al 2011 (143).  
 
2.14 Propidium Iodide 
Transfected, mock transfected, and control S3 cells underwent PI treatment to 
determine the efficiency of IDH2 in preventing cell death as previously described (144). 
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These S3 cells were subjected to 90 minutes of hypoxia in a hypoxia incubator chamber. 
Following hypoxia, the growth media was changed and cells were stained with 0.1 ug/ml 
Hoechst 33342 and 1.0 mg/ml PI for 20 minutes. These cells were then fixed using 4 % 
PFA for 25 minutes. Following fixation, PI positive cells were counted under a Nikon 
Livecell microscope with the 10x objective equipped for epifluorescence microscopy. 
 
2.15 In vivo Mitochondria Analysis 
  
2.15.1 Extracting the Kidney 
The rats were anesthetized with inactin hydrate. A midline incision was made and 
the kidney pedicle ligated and the kidney removed. Following isolation of the kidney, the 
kidney was placed onto an 0o C petri dish. Once placed onto the petri dish five mL of 
sterile saline was poured over the kidney. Following the washing of the kidney, the 
capsule was removed. Once the capsule was removed, the kidney was longitudinally 
bisected, using a razor blade to expose the cortex and medulla. Once exposed, the cortex 
was isolated, minced into fine pieces, and then weighed. Following the procedure, the 
animal was euthanized.  	
2.15.2 Electron Microscopy: Mitochondria Structure Analysis 
The specimens were fixed in 2% Paraformaldehyde 2% Glutaraldehyde in 0.1M 
phosphate buffer. After fixation, the specimens are rinsed with phosphate buffered saline 
(PBS) followed by post fixation with 1% osmium tetroxide in phosphate buffer for one 
hour. After rinsing again with PBS, the tissue specimens are dehydrated through a series 
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of graded ethyl alcohols from 70 to 100% concentration. After dehydration, the 
specimens were infiltrated with two changes of 100% acetone and a 50:50 mixture of 
acetone and the embedding resin (Embed 812, Electron Microscopy Sciences, Hatfield, 
PA) overnight. The next day the specimens are transferred to fresh aliquot of 100% 
embedding media for a minimum of two hours, then embedded in a fresh aliquot of 100% 
embedding media. Following polymerization overnight at 60°C the blocks are then ready 
to section. Thin sections were cut (70-80nm), stained with uranyl acetate and lead citrate, 
then viewed on a Tecnai BioTwin electron microscope (FEI, Hillsboro, OR) with digital 
images taken with an AMT (Advanced Microscope Techniques, Danvers, MA) CCD 
camera.  
 
2.15.3 PBI SG3 Shredder Mitochondria Homogenization 
The minced cortex was weighed and separated into groups of 300mg. Next, 300 
mg of cortex was positioned into the ram side of the pulse tube; the section was then 
capped closed and 700 microliters of mitochondria isolation buffer (250 mM Sucrose, 20 
mM HEPES ph 7.9, 10 mM KCl, 1.5 mM MgCl2, and 1.0 mM EDTA) was added to the 
cap side of the pulse tube; this section was capped closed. Next the tube was placed into 
the PBI Shredder and locked into position two. The shredder was run for 30 seconds and 
the supernatant was removed and placed into microcentrifuge tubes.   
 
2.15.4 Mitochondria Purification 
The mitochondria homogenate was centrifuged at 800x g for 10 minutes; after 10 
minutes the supernatant was transferred to a new set of microcentrifuge tubes and the 
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pellet was discarded. Next, the supernatant from the first centrifugation was centrifuged 
at 14,000x g for 10 minutes; after 10 minutes the supernatant was discarded and the pellet 
was resuspended in one mL of mitochondria isolation buffer. For the final spin, the pellet 
from round two was centrifuged at 14,000x g for 10 minutes; after 10 minutes the 
supernatant was discarded and the pellet is resuspended in 0.5 mL of mitochondria 
isolation buffer.  
 
2.15.5 Mitochondria Protein Measurement 
Following resuspension, the mitochondria lysate tubes were placed on ice for 
mitochondria respiration analysis using an Oroboros and three µL of each sample was 
removed for Bio-Rad Bradford Protein Assay (Bio-Tek Instruments, Inc) to determine 
mitochondria protein concentration.  	
2.15.6 Mitochondria Respiration Analysis: Oroboros Oxygraph-2k 
Mitochondria respiration analysis was conducted in an Oroboros Oxygraph-2k 
(Oroboros Instruments, Innsbruck, Austria) as previously described (145, 146). 
Equivalent amounts of mitochondria protein were loaded into a final volume of 2.0 mL 
miRO5 (110 nm sucrose, 20mM HEPES 20, 20mM taurine, 60 mM K-lactobionate, 3 
mM MgCl2, 10 mM KH2PO4, 0.5 mM EGTA 0.5 and 1 g l−1 bovine serum albumin, pH 
7.1) respiration buffer with constant stirring (750 rpm). Following mitochondria lysate 
addition, flux was allowed to stabilize before addition of substrates or ADP. Substrates 
were added in the following order and diluted to the following concentrations: 10 uM 
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Isocitrate, 2.5 uM Malate, 20 nM ADP, 7.5 uM Pyruvate, 20 nM ADP 10 uM Succinate, 
and 20 nM ADP. Flux was allowed to stabilize prior to addition of the next substrate or 
ADP. Data was collected using Oroboros Datlab version six and all calibration prior to 
experimentation was conducted according to Oroboros protocols (Figure 14).  
 
2.15.7 Mitochondria Membrane Potential Measurements: Tetramethylrhodamine 
Methyl Ester (TMRM) 
To determine changes in mitochondria membrane potential in response to HIFD, 
TMRM was infused via the tail vein in sham, pre-HIFD, and post HIFD rats. Ten fields 
were studied for each animal and statistical significance was determined at a p value less 
than 0.05 using Student’s t test.  
To evaluate changes in TMRM signal, 512x512 image scans were collected with 
simultaneous acquisition of 420nm and 514nm wavelengths at one scan per second using 
830nm excitation light in two-photon mode. 30 scans were acquired from each animal 
with random field selection. Images were acquired 20 (up but not exceeding 60 minutes) 
minutes post TMRM infusion in pre-HIFD rats 20 minutes and between 20-60 minutes 
post HIFD after HIFD. Images were also collected from sham-operated rats. Image 
intensity values were obtained by defining a circular region of interest (ROI). Average 
intensity values were obtained by placing the ROI over nuclei in all cells in a field using 
FIJI (134). 
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2.15.8 Mitochondria ATP Determination: High Performance Liquid 
Chromatography (HPLC) 
In vivo samples were isolated from animals that had undergone renal vein 
hydrodynamic fluid delivery, ischemic preconditioning, or control operations as 
previously described. One week later kidneys were immediately isolated and snap frozen 
and prepared for HPLC as previously described (147). The following steps were 
performed on ice at 4o C. Frozen whole kidneys were homogenized using a hand held 
mechanical tissue homogenizer in six mLs of pre-chilled 3% HClO4. Once the tissue was 
homogenized, the homogenate sat on ice for 10 minutes. After 10 minutes, the 
homogenate was centrifuged at 13,000 x g at 4o C for 10 minutes. The supernatant was 
transferred to a clean tube and one-third (300 µL) the volume of 3 M K2CO3 was added. 
The tubes were vortexed and placed on ice for 10 minutes. Following the incubation 
period, the samples were centrifuged at 13,000 x g at 4o C for 10 minutes and the 
supernatant was transferred to a clean microcentrifuge tube.  
 
2.16 In vitro Mitochondria Analysis 
 
2.16.1 Mitochondria Stress Test: Seahorse 
Mitochondria respiration analysis was conducted using a Seahorse XF 96 
extracellular flux analyzer as previously described (148). 5,000 MPTC S3 cells were 
plated in Seahorse XF 96 cell culture microplate 24 hours prior to analysis. Analysis was  
performed with the appropriate growth media containing 10 mM glucose, 100 mM 
sodium pyruvate and 1M glutamine. 
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Figure 14: Oroboros Oxygraph-O2k. The figure depicts mitochondria respiration 
analysis in an Oroboros. The blue line represents oxygen concentration, while the red line 
indicates represents oxygen flux. Substrates added include: Isocitrate (I), Malate (M), 
Pyruvate (P), Succinate (S), and ADP (D). 
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Cells were allowed to acclimate for one hour prior to analysis. Baseline measurements 
were conducted for transfected and mock transfected cells prior to compound addition. 
Respiration measurements were conducted following injections of 7 µM FCCP and 6 µM 
Rotenone/Antimycin A. All flux data is expressed in OCR, in pmol/min/cell (Figure 15).  
 
2.16.2 Mitochondria Membrane Potential Analysis 
MPTC S3 cells were transfected as previously described. Two days following 
transfection cells were plated onto a 96 well plate. One day later the JC-1 assay was 
performed as follows. 5 µM of JC-1 was added to depleted cell media and cells were 
placed in a hypoxia incubator chamber for 30 minutes. Following hypoxia, cell 
luminescence was measured using a spectrophotometer with an excitation wavelength of 
490 nm. Emission was measured at both 527 nm and 590 nm. Mitochondria membrane 
polarization was measured by ratioing 527nm to 590nm. Higher ratio values are 
indicative of higher membrane potential. 
 
2.16.3 Fluorescence Lifetime Imaging Microscopy: Determination of Cellular 
NAD(P)H Levels 
MPTC S3 cells were prepared and transfected as previously described. Following 
transfection, cells underwent fluorescence lifetime imaging microscopy (FLIM) as 
described by Gratton et al (149) and phasor plots were established and analyzed 
according to Winfree et al (150) and Digman et al (151).  
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Mitochondria lysates were isolated as previously described. 30 nM of Human 
Recombinant SULT1C2 protein, 20 µM PAPS, and 10 µM Laurdan were added to the 
sample and 50 µL were placed mounted on a slide and underwent FLIM a previously 
described.  
 
2.17 Western Blot Analysis 
Following isolation, the kidney was placed onto an 0o C petri dish. Once placed 
onto the petri dish 5 mL of sterile saline was poured over the kidney. Following the 
washing of the kidney, the capsule was removed. Once the capsule was removed, the 
kidney was longitudinally bisected, using a razor blade to expose cortex and medulla. 
Once exposed the cortex was isolated and minced into fine pieces and then weighed. The 
cortex was then homogenized, on ice in the cold room, using a dounce homogenizer and 
300 uL of RIPA buffer (150 mM NaCl, 50 mM Tris-Cl PH 8.0, 1% Triton X-100, 0.5% 
Sodium Deoxycholate, and 1% SDS) (ThermoFisher Scientific, Waltham, MA). Once 
homogenized, the lysate was transferred to a microcentrifuge tube. The lysate was 
centrifuged at 13,000 rpm for 15 minutes at 4oC. After this cycle, the supernatant was 
transferred to a clean microcentrifuge tube and sonicated. Following sonication, the tubes  
were centrifuged as previously described, and the supernatant was transferred to a clean 
tube. Protein concentration was determined using either BCA assay (ThermoFisher, 
Waltham, MA) or Bradford assay (Bio-Rad, Hercules, CA). 3 µg of protein was mixed 
with 2x Laemmli Sample Buffer and placed in a warming tray (70 oC for 10 minutes). 
Protein samples were then loaded into a 10% SDS Page Gel (Life Technologies, 
Carlsbad, CA) along with 8 µL of molecular weight standards 
68 
 
 
 
 
 
 
 
 
Figure 15: Seahorse Mitochondria Stress Test Graph. Graph detail changes in S3 
cell oxygen consumption. Addition of FCCP indicates maximal respiration, while 
the Rotenone/Antimycin A addition indicates complex II respiration. 
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The gel ran for 56 minutes at 200 V and was then electroblotted onto either nitrocellulose  
or PVDF membranes, depending on antibody recommendations, for 36 minutes at 24 V.  
 These membranes were then blocked in TBS with 3% FBS or TBS with 5% dry 
milk overnight at 4oC. Membranes were incubated in primary antibody in antibody 
dilution buffer (either 0.3% FBS in TBS or 5% dry milk in TBS) for one hour at room 
temperature. Membranes were then washed with TBST (TBS with Tween-20) and then 
incubated in secondary antibody in antibody dilution buffer for one hour at room 
temperature. After three more washes with TBST, the protein bands were visualized by 
chemiluminescence using SuperSignalTM West Pico Chemiluminescent Substrate 
(ThermoFisher, Waltham, MA). After a five-minute incubation period, the SuperSignal 
was removed and the membrane was wrapped in Polyvinyl Chloride wrap 
(ThermoFisher, Waltham, MA). Images were acquired using x-ray film in a darkroom.  
 
2.18 Statistical Analysis 
All statistical analyses were conducted using a two-tailed unpaired Student’s t-
test. Colocalization was determined using Mander’s localization analysis (143). All bar 
graphs are expressed as means ± s.d. 
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CHAPTER 3: REVERSAL OF ACUTE KIDNEY INJURY 
Paper: Collett JA, Corridon PR, Mehrotra P, Kolb AL, Rhodes GJ, Miller CA, 
Molitoris BA, Pennington JG, Sandoval RM, Atkinson SJ, et al. Hydrodynamic Isotonic 
Fluid Delivery Ameliorates Moderate-to-Severe Ischemia-Reperfusion Injury in Rat 
Kidneys. Journal of the American Society of Nephrology: JASN. 2017 (1). 
 
3.1 Photographic Analysis of Renal Vasculature following IRI 
Ischemic injuries can be broken down into two phases. The first phase is lack of 
blood flow to the kidney. The major effect of a reduction in blood flow is the loss of 
oxygen. The direct implication of oxygen loss is alteration in oxidative phosphorylation, 
specifically a Warburg Shift leading to heavy glycolytic metabolism. The second phase 
and probably the most detrimental is the reperfusion phase (45, 152). The reperfusion of 
blood into the kidney results in immune cell infiltration and red blood cell aggregation 
culminating in changes to renal vasculature. Ischemia reperfusion injury leads to changes 
in both epithelial and endothelial cell adhesion (8, 9, 42, 153, 154). To determine if our 
model of IRI caused changes in cell adhesion leading to the formation of red blood cell 
aggregates, termed rouleaux, typically seen with ischemic injury, we used correlative 
light and electron microscopy. Kidney sections were analyzed by light microscopy and 
then particular regions of interest were fixed for electron microscopy (Figure 16). In 
figure 16A, light microscopy indicates the aggregation of rouleaux (arrows) in the 
capillary lumen while 16B shows the same region at ultrahigh resolution. To compare 
ischemic and control kidneys, electron micrographs of uninjured kidneys were analyzed 
and non-aggregated red blood cells were observed, indicating lack of ischemic injury. 
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Figure 16 indicates the effect of reperfusion on the renal vasculature was similar to what 
has been reported in the literature (155, 156). 
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Figure 16: Microscopic Analysis of Kidneys Following Ischemic Injury. A) 
Multiphoton image of the renal vasculature. 150kD FITC dextran in green is taken up by 
the plasma, while red blood cells and rouleaux do not take up the dye. The images 
indicate formation of rouleaux (arrows) in the vascular space. B) Electron micrograph of 
A taken following fixation to depict renal structure following injury. C) Electron 
micrograph of uninjured renal vasculature. 
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3.2 The Amelioration of AKI by Hydrodynamic Isotonic Fluid Delivery 
The current clinical model for the treatment of AKI is to restore glomerular 
filtration rate and blood flow through the kidney. Our interest with hydrodynamic 
isotonic fluid delivery was to determine whether it would be translatable to the clinic. 
This technique has proven useful in the delivery of macromolecules to the kidney (22). 
We set out to determine if hydrodynamic isotonic fluid delivery could be used to change 
the prognosis and course of AKI. We hypothesized that this highly pressurized injection, 
ranging from 60-to-75 mmHG (Figure 11) and characterized by streaks of saline and 
blanching in the kidney (Figure 18), would alter the course of AKI by reducing vascular 
congestion.  
To study the effects of hydrodynamic isotonic fluid delivery on AKI, rats were 
subjected to IRI followed 24 hours later by renal vein hydrodynamic isotonic fluid 
delivery or injection in the vena cava. The animals were allowed to recover for four days 
and serum creatinine levels were analyzed to follow the course of injury. Figure 17 A-C 
indicate that animals that received hydrodynamic isotonic fluid delivery through the renal 
vein had reductions in SCr levels not seen in animals injected through the vena cava. The 
change in SCr, as indicated by figure 17 C was 1.65± 0.34 mg/dL. These findings were 
correlated with changes in renal morphology (Figure 19) and tissue injury scoring (Figure 
20). The images indicate acceleration in recovery and improved survival from IRI as a 
result of hydrodynamic isotonic fluid delivery that were not seen in animals that received 
vena cava injections (Figure 21). The culmination of the SCr data and morphological 
analysis indicate hydrodynamic isotonic fluid delivery can potentially alter the path of 
AKI.  
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Figure 17: Serum Creatinine Levels following Hydrodynamic Isotonic Fluid 
Delivery in Either Renal Vein or Vena Cava. SCr changes following IRI in animals 
treated with HIFD through the renal vein or vena cava control. A) SCr values 48 hours 
following injury and 24 hours’ post HIFD. B) SCr values four days post IRI and 72-hours 
post HIFD. C) The change in SCr 24 hours’ post HIFD includes values from two and four 
day groups. *P value <0.05 in HIFD versus vena cava. Statistics determined by unpaired 
student’s t-test. 
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Figure 18: Characteristics of Renal Physiology Prior to and Following 
Hydrodynamic Isotonic Fluid Delivery. Following HIFD, blanching and streaking is 
observed in the kidney (A) compared to three-minutes prior to injection (B). 
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Figure 19: Renal Histology 4-days post IRI. Hematoxylin and Eosin staining of 
cross-sections of the cortex and outer medulla. The renal histology indicates decreases in 
rouleaux (arrows) and vascular congestion in animals that received Hydrodynamic 
Isotonic Fluid Delivery. 
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Figure 20: Tissue Injury Scoring. Renal histology was used as a basis for tissue 
injury scoring of the cortex (A) and outer medulla (B). (C) Represents the total area of 
vascular congestion in renal cortex. *,$,# p value <0.05 for sham versus vena cava (*), 
HIFD versus vena cava (#), or sham versus HIFD ($). 
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Figure 21: Survival Graph. Hydrodynamic Isotonic Fluid Delivery improves 
survival in animals following an IRI by 70%. 
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3.3 Restoring Capillary Perfusion with Hydrodynamic Isotonic Fluid Delivery  
The histology shown in Figure 19 indicated decreased RBC accumulation in the 
vasculature following hydrodynamic isotonic fluid delivery. To test for changes in 
capillary perfusion, animals were subjected to IRI followed 24 hours later by 
hydrodynamic isotonic fluid delivery and intravital imaging of renal blood flow. Prior to 
hydrodynamic isotonic fluid delivery, I was able to identify areas in renal vasculature 
congested with rouleaux and hypoperfused (Figure 22 A). Following hydrodynamic 
isotonic fluid delivery, renal perfusion increased and rouleaux aggregation decreased 
leading to increased blood flow (Figure 22B; arrows). Blood flow analysis following IRI 
indicated an 81% reduction in blood flow velocity compared to sham treated animals. 
Following hydrodynamic isotonic fluid delivery, blood flow velocity increased 2.3-fold 
within 30 minutes of hydrodynamic isotonic fluid delivery compared to pre-
hydrodynamic isotonic fluid delivery groups (Figure 23). While still lower than sham 
animals, hydrodynamic isotonic fluid delivery increased blood flow rates significantly 
compared to animals that did not receive hydrodynamic isotonic fluid delivery.  
In addition to changes in perfusion in the kidneys, I also identified changes in cell 
membrane permeability. Hoechst 33342, which labels cell nuclei, has a molecular weight 
of 452g/mol, and due to its cell permanent properties is able to easily label cell nuclei. Its 
molecular weight is consistent with that of small therapeutic compounds generally used 
to treat kidney disease. 24 hours after IRI, Hoechst 33342 was injected via the tail vein 
and analyzed by intravital light microscopy. The fluorescence intensity signal was low in 
animals following IRI compared to sham treated animals (Figure 22 A-C). The average 
fluorescent intensity was 20.12±2.8 (au). Following hydrodynamic isotonic fluid 
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delivery, the intensity increased approximately 3.5-fold to 73.2±1.1 (au) (Figure 24). It is 
important to point out that during the hydrodynamic isotonic fluid delivery procedure no 
additional Hoechst 33342 was given indicating that increases in average fluorescence 
intensity are likely due to increased perfusion. To ensure that hydrodynamic isotonic 
fluid delivery was not detrimental to the vasculature, 150 kDa TRITC dextran was also 
injected through the tail vein. Figure 25 indicates that fluorescent intensity of interstitial 
space does not change as a result of hydrodynamic isotonic fluid delivery. Intravital 
imaging of renal vasculature before and after hydrodynamic isotonic fluid delivery 
indicates that hydrodynamic isotonic fluid delivery following IRI increases renal blood 
flow and cell permeability while decreasing rouleaux congestion.  
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Figure 22: Renal Blood Flow and Vascular Permeability. Multiphoton imaging of 
sham kidney(A), 24-hours post-IRI and pre-HIFD (B) and 24-hours post-IRI 20 minutes 
post-HIFD (C). Blue color is Hoechst 3342 staining of cell nuclei, red/orange is 150 kDa 
TRITC dextran. 
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Figure 23: Changes in RBC Velocity due to IRI and Hydrodynamic Isotonic Fluid 
Delivery. RBC velocity was calculated by conducting line scan analysis (Figure 13) 
according to Dunn et al and Lin et al (136, 157). The calculation of the slope of the line 
gives the overall velocity. ,#,$ p value <0.05 for sham versus post-HIFD ($), sham versus 
pre-HIFD(*), and pre-HIFD versus post-HIFD (#). 
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Figure 24: Permeability Changes in Response to Hydrodynamic Isotonic Fluid Delivery. 
The average mean fluorescence intensity was calculated from 10 ROI from three separate 
experiments for sham, pre-HIFD and post-HIFD. *,#,$ p value <0.05 for sham versus 
post-HIFD ($), sham versus pre-HIFD(*), and pre-HIFD versus post-HIFD (#). 
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Figure 25: Analysis of Interstitial Vascular Leakage. Analysis of permeability 
changes in interstitial space as a percentage of tubular fluorescence in response to 
Hydrodynamic Isotonic Fluid Delivery. 10 ROI from three separate experiments for 
sham, pre-HIFD and post-HIFD were analyzed. *,#,$ p value <0.05 for sham versus post-
HIFD ($), sham versus pre-HIFD(*). 
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3.4 The Effects of Hydrodynamic Isotonic Fluid Delivery on Infiltrating 
Mononuclear Cells 
To better understand the role of inflammatory cells in IRI, we analyzed 
mononuclear cell populations 48 hours following injury by fluorescence activated cell 
sorting (FACS). Following injury, we noticed increases in CD4+, CD8+, B, CD4+17+, 
CD8+17+, and DC/Macrophage populations compared to control uninjured animals. The 
effects of hydrodynamic isotonic fluid delivery on mononuclear cells was astounding as 
we noticed significant reductions on all previously mentioned cell populations compared 
to vena cava control injections (Figure 26). hydrodynamic isotonic fluid delivery 
following IRI reduces the number of infiltrating mononuclear cells thereby preventing 
increases in vascular congestion and inflammation associated with IRI (Figure 27) (Table 
5). 
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Figure 26: Effects of Hydrodynamic Isotonic Fluid Delivery on Infiltrating 
Mononuclear Cells. To determine if Hydrodynamic Isotonic Fluid Delivery reduced the 
number of infiltrating mononuclear cells, kidneys from sham, IRI plus vena cava 
injection, and IRI plus Hydrodynamic Isotonic Fluid Delivery were isolated for FACS 
analysis. (A) The total number of infiltrating cells in the kidney. (B) IL 17+CD4+, (C) 
IL17+CD8+. Data depicts the mean number of cells per gram kidney. *,#,$ p value <0.05 
for sham versus post-HIFD ($), sham versus pre-HIFD(*), and pre-HIFD versus post-
HIFD (#).  
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Figure 27: Renal Vein Hydrodynamic Isotonic Fluid Delivery Reduces Total 
Infiltrating Cell Number. Hydrodynamic Isotonic Fluid Delivery reduces the size of the 
cell pellet (from whole kidney) compared to vena cava injections. 
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Table 5: The Effect of Hydrodynamic Isotonic Fluid Delivery on Infiltrating 
Mononuclear Cells. 
  
ap< 0.05 sham versus IRI + a vena cava. bp<0.05 in IRI + vena cava versus 
IRI +HIFD  
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3.5 Hydrodynamic Isotonic Fluid Delivery: From Bench to Bedside 
A critique of hydrodynamic isotonic fluid delivery is the presence of an arterial 
clamp. In a clinical setting, clamping the renal artery is not ideal and unlikely to be 
practiced. To determine if hydrodynamic isotonic fluid delivery is translatable to the 
clinic, we repeated our experiments in the absence of an arterial clamp, leaving only the 
renal vein clamped. We observed similar reductions in SCr following hydrodynamic 
isotonic fluid delivery compared to vena cava injected animals (28A). In addition to 
reductions in SCr, we also observed similar decreases in CD4+, CD8+, B, CD4+17+, 
CD8+17+, and DC/Macrophage populations compared to vena cava injected controls 
(28B-F). Finally, our blood flow analysis indicated increases in RBC velocity similar to 
the increases seen when the arterial clamp was applied (28G). In its entirety, Figure 28 
indicates that the arterial clamp has no measurable effect on the hydrodynamic isotonic 
fluid delivery process and that hydrodynamic isotonic fluid delivery has the potential to 
reduce vascular congestion, increase RBC velocity following IRI, and reduce the 
inflammatory effect typically seen following injury. 
 
90 
 
 
 
Figure 28: Hydrodynamic Isotonic Fluid Delivery Improves Renal Function 
Regardless of Arterial Clamping. This figure illustrates Hydrodynamic Isotonic Fluid 
Delivery is translatable to the clinic. HIFDRV only sees similar reductions in SCr at two-
days post IRI compared to vena cava injected animals (A). There are also decreases in 
infiltrating mononuclear cells compared to vena cava injected animals (B-E), and 
decreases in total number of infiltrating cells compared to vena cava injected animals (F). 
Finally, HIFDRV improves RBC velocity similar to the results from figure 22. *,#,$ p 
value <0.05 for sham versus post-HIFD ($), sham versus pre-HIFD(*), and pre-HIFD 
versus post-HIFD (#).  
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3.6 The Effects of Hydrodynamic Isotonic Fluid Delivery on Mitochondria 
The effects of hydrodynamic isotonic fluid delivery as a potential therapeutic for 
AKI cannot be ignored. We have demonstrated that hydrodynamic isotonic fluid delivery 
following IRI has the potential to increase GFR and urine output leading to reductions in 
SCr. We were able to demonstrate that the potential mechanism of these reductions was 
related to decreases in vascular congestion and mononuclear cell infiltration allowing 
increases in renal blood flow. As a next step, I decided to analyze the effect of 
hydrodynamic isotonic fluid delivery on mitochondria membrane potential. Following 
injury, mitochondria activity changes leading to a reduction in oxidative phosphorylation 
and membrane potential allowing increases in reactive oxygen species and potential 
activation of apoptotic pathways. To determine if hydrodynamic isotonic fluid delivery 
has the potential to increase mitochondria activity and promote cell survival following 
injury, TMRM was injected via the tail vein 24 hours after IRI and intravital imaging of 
renal mitochondria occurred pre-and post-HIFD. 24 hours after injury, mitochondria 
membrane potential was low indicating low levels of mitochondria activity. Following 
hydrodynamic isotonic fluid delivery, mitochondria membrane potential improves 
suggesting increases in mitochondria activity (Figure 29). Fluorescent quantification of 
mitochondria membrane potential indicated that hydrodynamic isotonic fluid delivery 
leads to a three-fold increase in mitochondria activity (Figure 30). Increases in 
mitochondria membrane potential following hydrodynamic isotonic fluid delivery 
indicate another mechanism in disease reversal. As previously mentioned, the increase in 
potential was linked to an increase in oxidative phosphorylation, alleviation of ROS 
typically seen following ischemia, and prevention of cell death cascades (62),(67). 
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Figure 29: The Effects of Hydrodynamic Isotonic Fluid Delivery on Mitochondria 
Membrane Potential. To analyze mitochondria membrane potential following AKI, 
animals were subjected to an ischemic injury. A) Membrane potential in a sham animal, 
B) 24-hours post-injury and pre-HIFD, and C) 24-hour post-injury and 30 minutes post-
HIFD.  
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Figure 30: Quantification of the Effects of Hydrodynamic Isotonic Fluid Delivery on 
Mitochondria Membrane Potential. N of three animals per group. Hydrodynamic Isotonic 
Fluid Delivery increases mitochondria membrane potential 24 hours following injury. 
The average mean TMRM fluorescence intensity was calculated from 10 ROI from three 
separate experiments for each group. *,#,$ p value <0.05 for sham versus post-HIFD ($), 
sham versus sham-HIFD(*), and pre-HIFD versus post-HIFD (#). 
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CHAPTER 4: PREVENTION OF AKI BY MIMICKING ISCHEMIC 
PRECONDITIONING  
Paper: Kolb et al., Exogenous Gene Transmission of Isocitrate Dehydrogenase-II Mimics 
Late Window Ischemic Preconditioning Protection 
 
4.1 Hydrodynamic Delivery does not Damage Renal Mitochondria  
Hydrodynamic delivery is a useful tool in the reversal of AKI (Chapter 3). Collett 
et al were able to demonstrate that hydrodynamic isotonic fluid delivery increased 
vascular perfusion and blood flow by reducing vascular congestion and number of 
infiltrating mononuclear cells (1). Corridon et al have also shown that hydrodynamic 
delivery is capable of delivering macromolecules to the kidney (22). As mentioned 
previously, mitochondria are a target of AKI. We set out to determine if gene delivery to 
mitochondria was possible employing this technique, and if so, how this protection is 
established.  
Prior to conducting gene delivery experiments, we analyzed effects of the high-
pressure forces of hydrodynamic delivery on mitochondria using electron microscopy. 
Normal mitochondria physiology includes: ovular shape, dense matrix and parallel cristae 
(158). Figure 31 and 32 depict renal mitochondria from a sham animal that did not 
receive an injection and from a hydrodynamic isotonic fluid delivery animal. The figures 
indicate that the pressure forces generated by the injection did not change morphology of 
mitochondria (Figure 31 and 32). 
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Figure 31: Electron Micrograph of Sham Animals That Did Not Receive Renal Vein 
Injections have normal appearing mitochondria (arrows). 
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Figure 32: EM Image of Renal Mitochondria Following Hydrodynamic Delivery. 
Mitochondria (arrows) physiology appears normal. 
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4.2 Proteomic Analysis of IPC 
IPC was induced by subjecting rats to bilateral renal IRI for 30 minutes followed 
by recovery for 14 days, resulting in the resolution of serum creatinine back to levels in 
sham-operated controls. As expected, this maneuver significantly attenuated the elevation 
in serum creatinine in rats 24-hours following a second ischemic insult (Figure 33). Renal 
cortical mitochondria were isolated from IPC or sham IPC rats at 14 days and used for a 
proteomic screen. Table four shows the proteins that are significantly altered in IPC rat 
kidney versus sham IPC rat kidney. 12 proteins were significantly altered, (six increased, 
six decreased compared to sham IPC animals) by the 14 day IPC protocol (Table 4). Of 
these, IDH2 was chosen for further analysis due to its function in the TCA cycle and as a 
branch point enzyme for lipid and protein synthesis. To confirm these findings, we 
repeated the IPC protocol and conducted immune blots for IDH2 on mitochondria 
isolated from renal cortex, demonstrating an approximate 10-fold increase in IDH2 when 
compared to control rats (Figure 34). 
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Figure 33: Analysis of the Effects of IPC on SCr. Rats were subjected to sham, 
sham-IPC, and IPC surgeries and subsequent IRI evaluated by SCr after 24 hours. (p 
<0.05 Sham IPC versus IPC). 
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Figure 34: Gene Delivery of IDH2 Shows Similar Levels of IDH2 as IPC. 
Immune blot of IDH2 in animals injected with saline, IDH2, or following IPC. Side panel 
illustrates the ratio of IDH2 to Actin using FIJI (*p <0.05 IDH2 versus vehicle; # p<0.05 
IPC versus vehicle). 
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4.3 IDH2 Protection Against Hypoxia Injury 
Initial screening of IDH2 activity utilized immortalized murine renal proximal 
tubule S3 cells (MPTC), which were derived from a large T antigen mouse through direct 
microscopic dissection and have been used in studies of acute ischemic injury and 
nephrotoxic kidney injury (159, 160). To confirm that exogenous IDH2 targets 
mitochondria, in vitro transfection was performed using a N-terminal myc-tagged IDH2. 
Multi-photon imaging revealed that myc-tagged IDH2 clearly localized in mitochondria 
stained with Mitotracker red (Figure 35 a-e). The Manders coefficient for colocalization 
was 0.8, indicating a high degree of mitochondria colocalization (143). S3 cells 
transfected with plasmids bearing IDH2 were resistant to necrosis following hypoxia as 
compared to mock transfected cells (9%±7.8% versus 42%±27.6%; p<0.05; Figure 36). 
Cells transfected with IDH2 maintained higher intracellular ATP/AMP ratios even in 
response to hypoxia (Figure 37) and have elevated mitochondria membrane potential 
(Figure 38). These increases in membrane potential were also linked with improved cell 
health and survival (Figure 36; p<0.05; and 38). 
 
 
  
101 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 35: IDH2 Localization to the Mitochondria. IDH2 myc localization in NIH 
3T3 cells. NIH 3T3 cells were transfected with N terminal myc-tagged IDH2 (e) or cells 
not transfected (a). The blue channel shows Hoechest labeling (b), the green channel 
shows myc IDH2 (c), and the red channel shows Mitochondria (d).  
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Figure 36: IDH2 Reduces Cell Death. Quantitative analysis of propidium iodide 
cells. Following transfection, S3 cells were subjected to 90 minutes of hypoxia in a 
hypoxia incubator chamber. Following hypoxia, the growth media was changed and cells 
were stained with 0.1 ug/ml Hoechst 33342 and 1.0 mg/ml PI for 20 minutes. IDH2 
reduces cell death relative to control (*p <0.05 Hypoxic IDH2 versus Hypoxic control). 
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Figure 37: IDH2 Increases ATP/AMP Ratios in vitro. ATP/AMP ratios in MPTC 
S3 with or without IDH2 and hypoxia (* denotes p<0.05 hypoxic IDH2 versus hypoxic 
control; # p<0.05 IDH2 versus control). 
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Figure 38: IDH2 Alters Mitochondria Membrane Potential. JC-1 fluorescence 
intensity ratios in MPTC S3 with or without IDH2 following hypoxia increases following 
IDH2 transfection (*p<0.05 Mock versus IDH2). 
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Figure 39 depicts the effects of IDH2 transfection on mitochondria respiration in 
S3 cells. Baseline oxygen consumption rate (OCR) of MPTC S3 cells was 29.4±6.8 
pmol/min/cell, while transfection with IDH2 significantly increased the OCR to 41±2 
pmol/min/cell (Figure 40). Maximal uncoupled respiratory capacity following addition of 
FCCP was also enhanced by IDH2 transfection (Figure 41). Complex II OCR, evaluated 
following the addition of Rotenone and Antimycin A (inhibitors of Complex I and III), 
was also significantly increased by IDH2 transfection (Figure 42). Our final in vitro 
analysis was to test if IDH2 over expression affected reserve or spare respiratory capacity 
(SRC). This is measured as the difference between maximal respiration and baseline 
respiration. Normal S3 cell SRC was 23.5±8.4 pmol/min/cell. In cells transfected with 
IDH2, SRC was 31.9±11 pmol/min/cell indicating the addition of IDH2 increased MPTC 
SRC (Figure 43).  
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Figure 39: In vitro Mitochondria Respiration Analysis. Respiration was analyzed using a 
Seahorse. 7 µM FCCP and 6 µM Rotenone and Antimycin A were added to determine 
the effects of IDH2 on different respiratory states. 
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Figure 40: Baseline OCR in MPTC S3 Cells. IDH2 transfection increases baseline 
OCR. (* denotes p<0.05 IDH2 versus control; # denotes p<0.05 myc IDH2 versus 
control; $ denotes p <0.05 myc IDH2 to mock; ** denotes p<0.05 IDH2 versus mock). 
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Figure 41: Maximal OCR in MPTC S3 Cells. IDH2 transfection increases 
maximum OCR. (* denotes p<0.05 IDH2 versus control; # denotes p<0.05 myc IDH2 
versus control; $ denotes p <0.05 myc IDH2 to mock; ** denotes p<0.05 IDH2 versus 
mock).  
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Figure 42: Complex II OCR in MPTC S3 Cells. IDH2 transfection increases 
Complex II OCR. (* denotes p<0.05 IDH2 versus control; # denotes p<0.05 myc IDH2 
versus control; $ denotes p <0.05 myc IDH2 to mock; ** denotes p<0.05 IDH2 versus 
mock).  
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Figure 43: SRC OCR in MPTC S3 Cells. Maximal respiration minus baseline 
respiration was used to calculate SRC. IDH2 transfection increases SRC OCR. (* denotes 
p<0.05 IDH2 versus control; ** denotes p<0.05 IDH2 versus mock). 
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4.4 Gene Delivered IDH2 Targets to Mitochondria 
Retrograde hydrodynamic injection of plasmid cDNA through the renal vein has 
been shown to be an effective means of facilitating exogenous gene expression in the rat 
kidney (22). To evaluate the effects of IDH2 up-regulation in the kidney, N-terminal 
myc-tagged IDH2 or saline was delivered by hydrodynamic injection. After seven days 
of recovery, isolated renal cortical mitochondria contained approximately three-fold 
higher levels of IDH2 versus animals injected with saline alone, as indicated by immune 
blots (Figure 44). These data indicate that hydrodynamic delivery of IDH2 results in 
sustained expression of protein in proximal tubule mitochondria to levels comparable to 
that observed during resistance to IRI following IPC.  
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Figure 44: Myc-tagged IDH2 Localizes to the Mitochondria. Representative 
immune blot of protein (5 µg) from mitochondria extracts. Lanes 1-3 are saline only and 
lanes 4-6 are myc-tagged IDH2. Band densitometry (right panel) of ratio of myc-tagged 
IDH2/Actin is shown (*p<0.05 myc IDH2 versus vehicle). 
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4.5 IDH2 Mimics IPC in changing Mitochondria Membrane Potential 
Since IDH2 was found to localize to mitochondria, we analyzed changes in 
mitochondria function in response to IRI. Mitochondria polarization was evaluated with 
TMRM and intravital imaging. Following two weeks of IPC (i.e. 14 days following 
recovery from 35 minutes of IRI), the TMRM signal from rat kidney tubules was 
significantly elevated relative to that observed in sham-IPC control rats (Figure 45a and 
d). Similarly, rats subjected to IDH2 delivery have significantly increased TMRM signal 
relative to saline injected control animals (Figure 45b-c and Figure 46). To evaluate 
whether IDH2 delivery in vivo influenced mitochondria respiration, renal cortical 
mitochondria were isolated and analyzed using oximetry. Respiration was measured in 
response to isocitrate, pyruvate, and succinate to evaluate complex I and II activity. 
Mitochondria isolated from IDH2 treated animals showed increased state II and state III 
respiration relative to saline injected animals, regardless of the substrate utilized (Figure 
47). A potential mechanism for increased membrane potential was increases in reduction 
potential and reduction potential stores. We analyzed NAD(P)H levels using FLIM and 
found minimal changes in these reduction potential stores (Figure 48 and 49). Indicating 
the importance of maintaining cellular reduction pool ratios.  
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Figure 45: Mitochondria Membrane Potential Following Gene Delivery and IPC. 
TMRM labeled mitochondria by intravital microscopy in sham rats (a), rats after 
injection of saline(b), IDH2 (c) or following IPC (d).  
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Figure 46: Quantification of TMRM Intensities. Intensities from Figure 44 a-d were 
averaged giving a mean TMRM intensity value (n=50 tubules per rat; three rats per 
group; *p <0.05 IDH2 versus vehicle # p <0.05 IPC versus vehicle). 
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Figure 47: Mitochondrial oximetry from Isolated Renal Mitochondria. Respiration 
of isolated renal mitochondria one week after saline or IDH2 injections. Oxygen flux was 
assayed following addition of: Isocitrate (I), Malate (M), Pyruvate (P), Succinate (S), and 
ADP (D)(n=3/group). (IMD- Isocitrate, Malate and ADP; * p <0.05 IDH2 versus vehicle) 
(IMPD-Isocitrate, Malate, Pyruvate and ADP; # p <0.05 IDH2 versus vehicle) (IMPSD- 
Isocitrate, Malate, Pyruvate, Succinate and ADP; $ p <0.05 IDH2 versus vehicle). 
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Figure 48: FLIM of NAD(P)H. Transfection with IDH2 causes minimal change in 
the reduction potential. Colors indicate different regions of interest on the phasor plot in 
Figure 49.  
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Figure 49: FLIM Phasor Plot. Plot shows minimal changes in reduction potential 
stores. Shifts toward zero indicate increased FAD, while shifts toward one indicate 
increased NADH. Gene transfection does not increase reduction potential and there is no 
statistical difference between groups. 
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4.6 IDH2 Increases Oxidative Phosphorylation and Prevents Tissue Injury 
To determine if IDH2 delivery mimics IPC, we subjected rats to either IPC or 
IDH2 delivery and allowed them to recover. As expected, IPC treated rats were resistant 
to IRI as indicated by reduced serum creatinine 24 hours following IRI, relative to sham 
IPC. Interestingly, IDH2 resulted in a similar reduction in SCr (Figure 50) and improved 
tissue histology in response to IRI (Figure 51 and 52). Analysis of mitochondria 60 
minutes following reperfusion demonstrated that IDH2 preserved respiratory capacity 
relative to vehicle controls (Figure 53). Finally, IPC and IDH2 delivery both increased 
ATP levels versus sham and saline injected control animals indicating IDH2 enhances 
ATP stores, thereby protecting against IRI (Figure 54).   
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Figure 50: IDH2 Mimics IPC and Blunts SCr Increase. Comparison of SCr 
following IPC or IDH2 delivery 24 hours following IRI (*p < 0.05 IDH2 versus vehicle; 
#p < 0.05 IPC versus vehicle). 
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Figure 51: Tissue Histology Detailing the Effects of IDH2 on Injury Prevention. 
Hematoxylin and Eosin stained section of renal outer medulla following IRI in rats 
treated with saline (a) or IDH2 injection (b) is shown. 
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Figure 52: Quantitation of Tissue Histology. Corresponding injury scoring for 
Figure 48 (# p<0.05 IRI IPC versus IRI Saline; *p<0.05 IRI IDH2 versus IRI saline). 
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Figure 53: The Protective Effects of IDH2 on Mitochondria Oximetry. 
Mitochondria respiration one hour following IRI in vehicle or IDH2 treated rats is shown 
with pyruvate (A) or succinate (B) as a substrate (A-B; n=4 per group; * p<0.05 IDH2 
IRI versus vehicle IRI). 
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Figure 54: Analysis of IDH2 on ATP/AMP Ratio in vivo. Renal ATP/AMP ratio 
is shown in sham, vehicle, IDH2, and IPC treated rats. (*p < 0.05 IDH2 versus vehicle; 
#p < 0.05 IPC versus sham).  
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CHAPTER 5: ADDITIONAL STUDIES  
5.1 Analysis of Epithelial Tight Junction Proteins Following Ischemia  
 
5.1.1 Abstract 
Tight junction proteins are critical regulators of cell leak and membrane polarity. 
Ischemic injuries to tight junctions decrease the cells’ ability to maintain this control, 
leading to increases in the leak state and decreases in membrane polarity. However, our 
in vivo data indicates ischemia increases the rate of tight junction turnover compared to 
pre-ischemic tight junctions. To test the mobility of tight junctions, adenoviral GFP 
occludin was hydrodynamically delivered through the renal vein. Four days later the 
kidney was exposed for intravital microscopy and labeled tight junctions were selected 
for FRAP. FRAP was conducted on both pre-and post-ischemic tight junctions and on 
control regions. Cells were treated with 0 µM H2O2, 55 µM H2O2 or 110 µM H2O2 for 2 
hours at 37o C before FRAP. Control cells treated with 0 µM H2O2 have an immobility of 
43% ± 14% with a half-life of 68.2 ±17.3 seconds. Cells treated with 55 µM H2O2 have 
an immobility of 32% ±16% with a half-life of 88.5 ±23.7 seconds. Cells treated with 110 
µM H2O2 have an immobility of 37% ±15% with a half-life of 82.3 ±21.03 seconds. For 
our animal model, tight junction or non-tight junction regions of the apical membrane 
were selected for FRAP. The immobility of pre-ischemic tight junctions is 93% ±9%. 
The immobility of ischemic tight junctions is 34% ±24%. The average half-life recovery 
of ischemic tight junctions is 23.13 ±1.07 seconds. The pre-ischemic tight junctions show 
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minimal recovery at 180 seconds following FRAP. Results are statistically significant 
with a p value <0.05.  
 
5.1.2 Background 
Tight junctions are located on apical surfaces of adjoining cells. They are 
composed of various proteins such as occludin, claudin, and cingulin. The primary 
responsibility of these junctions is to regulate the movement of ions, solutes, and other 
molecules around the cell, establishing a paracellular permeability layer. Construction of 
this permeability layer by tight junctions establishes two diffusion pathways: the pore and 
leak pathway. The pore pathway allows the diffusion of small solutes at high capacity, 
while the leak pathway allows the diffusion of large solutes at low capacity (161). The 
role of paracellular permeability has been well characterized in disease, including kidney 
disease (162). It is believed that occludin is a regulator of paracellular permeability and 
thus a target of renal disease triggered by ischemic injuries. Ischemic injury to tight 
junctions increases paracellular leak and degradation of tight junctions. To study the 
importance of tight junction proteins in vitro, we used increasing concentrations of H2O2, 
seen to increase during ischemia contributing to decreased paraceullular permeability and 
enhanced ischemic injury, to induce ischemia (163, 164). We used FRAP, or fluorescence 
recovery after photobleaching, to analyze the movement of occludin (labeled with GFP) 
into tight junctions. To study these effects in vivo, animals were injected with the same 
occludin constructs through the renal vein and FRAP was used to analyze occludin 
movement before and after ischemia.  
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5.1.3 FRAP Analysis of MDCK Tight Junctions 
To determine occludin mobility in vitro, MDCK cells were transfected with GFP 
occludin, occludin 840 truncation GFP, and occludin ZO-1 binding domain deletion GFP. 
These cells were then exposed to increasing concentrations of H2O2 and underwent 
FRAP. Cells transfected with occludin GFP have increased immobility compared to cells 
transfected with the other constructs and decreased immobility with increasing H2O2 
concentrations (Figure 55). Analysis of half-life indicated that increasing concentrations 
of H2O2 decrease the time it takes for these proteins to move into tight junctions (Figure 
56). These data point to ischemia slowing the movement of the occludin proteins into 
tight junctions. 
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Figure 55: Analysis of Immobility of Occludin in MDCK Cells in Response to 
Injury. Cells were transfected with either GFP occludin, occludin 840 truncation, or ZO-1 
binding site deletion and exposed to increasing concentrations of H2O2 (* p<0.05 0 uM 
versus 55uM GFP occludin).  
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Figure 56: Analysis of Occludin Half-Life in Response to Injury. Cells were 
transfected with either GFP occludin, occludin 840 truncation, or ZO-1 binding site 
deletion and exposed to increasing concentrations of H2O2 (* p<0.05 0 uM versus 55uM 
GFP occludin; $ p<0.05 05 0 uM versus 110 uM GFP occludin; #, p<0.05 05 0 uM 
versus 55uM ZO-1 deletion). 
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5.1.4 FRAP Analysis of Tight Junction Proteins In vivo  
To determine if tight junction mobility decreases in vivo, we used hydrodynamic 
delivery to inject animals with the same occludin constructs used in our in vitro models. 
Figure 57 indicated high immobility of occludin prior to ischemia, but a significant 
decrease in immobility following ischemia contrary to our in vitro data. Analysis of half-
life also indicated increased occludin turnover following ischemia compared to control 
and in vitro models (Figure 58). Our in vivo data indicates that rather than increasing 
occludin immobility, ischemia decreases immobility aiding in tight junction recovery 
following injury.  
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Figure 57: Analysis of Tight Junction Immobility in vivo. Rats received hydrodynamic 
delivery of adenoviral GFP occludin or occludin 860 truncation and four days later 
underwent FRAP before and after ischemia (n=4 per group; *p<0.05 WT pre- ischemia 
versus occludin mutant pre-ischemia; $ p<0.05 WT pre-ischemia versus WT post-
ischemia; # p<0.05 occludin mutant pre-ischemia versus occludin mutant post-ischemia). 
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Figure 58: Analysis of Occludin Half-Life Following Ischemia. Rats received 
hydrodynamic delivery of adenoviral GFP occludin or occludin 860 truncation and four 
days later underwent FRAP before and after ischemia. Graph shows half-life of 
fluorescent recovery following photobleaching (n=4 per group; *p<0.05 WT versus 
mutant). 
  
133 
 
 
5.1.5 Conclusion 
Paracellular leak is a potential mechanism for renal epithelial cell death. While 
the main cause remains unclear, what we know is that ischemic injuries target tight 
junction proteins such as occludin and increases in H2O2 exacerbate this injury (161, 
163). Our data indicate that occludin turnover is slow following injury and that this may 
contribute to an increased leak state. Using this information, we analyzed the leak 
pathway in our animal model. Using hydrodynamic gene delivery, we imaged occludin in 
vivo, both before and after ischemia. Contrary to our cellular model, we found that 
ischemia increases tight junction mobility and recovery (Figure 57 and 58) thus 
decreasing the cellular leak state. The importance of occludin in our model cannot be 
understated. The introduction of occludin mutants in our data shows decreased mobility 
and recovery of fluorescence. To continue to analyze the role of occludin and other tight 
junction proteins in recovery, we plan to deliver other occludin mutants such as a ZO-1 
binding site deletion and assay mobility and half-life in vivo. In the future, we plan to 
hydrodynamicly deliver other proteins such as claudin to determine the effects on claudin 
on tight junctions. 
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5.2 Gene Delivery of Sulfotransferase 1C2 (SULT1C2) 
 
5.2.1 SULT1C2 Post-Translationally Increases Mitochondria Respiration.  
Sulfotransferases are enzymes responsible for xenobiotic detoxification. 
Mechanistically, these enzymes add a sulfate group to xenobiotics which increases their 
water solubility and urinary excretion. We identified SULT1C2 in a proteomic screen of 
mitochondria isolated from ischemic preconditioned kidneys. Using hydrodynamic gene 
delivery, we show that SULT1C2 protects against subsequent ischemia one week after 
gene delivery. To determine SULT1C2’s mechanism of action, we assayed mitochondria 
function with and without human recombinant SULT1C2 and its substrate, 3’ 
Phosophoadenosine-5’-phosophosulfate (PAPS). Mitochondria respiration was assayed 
using an Oroboros Oxygraph O2K. We found that that PAPS and SULT1C2 incubated 
with mitochondria increase mitochondria state III respiration (from 139.4 ±36 to 370.7 ±32	pmol/min/mg), following succinate and rotenone addition, 2.7-fold compared to 
mitochondria (P<0.05). The increase in SULT1C2/PAPS dependent respiration was 
inhibitable with antimycin A but not rotenone. In conclusion, SULT1C2 and PAPS 
increase the efficiency of complex II respiration indicating a potential change in the 
movement of electrons through the complex culminating in increased oxidative 
phosphorylation. This is a novel function for an enzyme that heretofore was considered to 
be solely involved in detoxifying xenobiotics. 
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5.2.2 SULT1C2 Mimics IPC Similar to IDH2  
SULT1C2 was identified in the same proteomic screen that detected IDH2. 
SULT1C2 was upregulated 2.4-fold compared to sham IPC animals, which is 0.2-fold 
higher then IDH2 (Table 4). To determine if SULT1C2 delivery mimics IPC, we 
subjected rats to either IPC or SULT1C2 delivery and allowed them to recover. As 
expected, IPC treated rats were resistant to IRI as indicated by reduced serum creatinine 
24 hours following IRI, relative to sham IPC. Interestingly, SULT1C2 resulted in a 
similar reduction in SCr (Figure 59), and improved tissue histology scoring in response to 
IRI (Figure 60 and 61). Analysis of mitochondria 60 minutes following reperfusion, 
demonstrated SULT1C2 preserved respiratory capacity relative to vehicle controls 
(Figure 62). In a similar fashion to IDH2 and IPC, SULT1C2 was also found to increase 
mitochondria membrane potential indicating both in vitro and in vivo a potential 
mechanism for study (Figure 63 -64). 
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Figure 59: SULT1C2 Mimics IPC and Blunts SCr increase. Comparison of SCr 
following IPC or SULT1C2 delivery 24 hours following IRI (*p < 0.05 IDH2 versus 
vehicle; #p < 0.05 IPC versus vehicle). 
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Figure 60: Tissue Histology Detailing the effects of SULT1C2 on Injury 
Prevention. Hematoxylin and Eosin stained section of renal outer medulla following IRI in 
rats treated with saline (a) or SULT1C2 injection (b). 
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Figure 61: Quantitation of Tissue Histology. Corresponding injury scoring for 
Figure 60 (# p<0.05 IRI IPC versus IRI Saline; *p<0.05 IRI SULT1C2 versus IRI saline). 
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Figure 62: The Protective Effects of SULT1C2 on Mitochondria Oximetry. 
Mitochondria respiration one hour following IRI in vehicle or SULT1C2 treated rats is 
shown with pyruvate (white) or isocitrate (black) as a substrate (n=4 per group; * p<0.05 
SULT1C2 IRI versus vehicle IRI. 
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Figure 63: SULT1C2 Increases Mitochondria Membrane Potential in vitro. JC-1 
fluorescent intensity ratios in MPTC S3 with or without SULT1C2 following hypoxia. 
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Figure 64: Mitochondria Membrane Analysis Following Gene Delivery and IPC. 
TMRM labeled mitochondria by intravital microscopy in sham rats (A), rats following 
injection of saline (B), SULT1C2 (C) or following IPC (D).  
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5.2.3 Characterizing the Mechanism of SULT1C2 
To determine the mechanism of protection of Sulfotransferase 1C2, human 
recombinant SULT1C2 and its substrate PAPS were added to isolated mitochondria. 
Analysis of mitochondria respiration indicated that mitochondria treated with both 
SULT1C2 and PAPS had a 2.7-fold increase in state III respiration following Succinate 
addition compared to control mitochondria (Figure 65). This increase in SULT1C2/PAPS 
dependent respiration was inhibitable with antimycin A but not rotenone. As a potential 
mechanism for this increase in respiration we analyzed changes in mitochondria 
membrane fluidity using Laurdan and Fluorescence Lifetime Imaging Microscopy 
(FLIM). The addition of Laurdan to the SULT1C2/PAPS sample shows a decrease in the 
Fluorescent Lifetime of Laurdan compared to control mitochondria (Figure 66). This 
indicates a potential decrease in mitochondria membrane fluidity and a potential increase 
in the efficiency of electron movement through mitochondria complexes. This decrease in 
fluidity was the result of the addition of a sulfate group to either proteins or lipids on the 
mitochondria surface. We eliminated the possibility of protein sulfation by immune blot. 
Our data indicates that mitochondria with SULT1C2/PAPS contained membrane proteins 
with 4-fold lower sulfate levels then control mitochondria (Figure 67). To determine the 
possibility of lipid sulfation we measured mitochondria respiration in the presence of 
cholesterol sulfate. Our data indicates the addition of cholesterol sulfate increases 
mitochondria state three respiration to levels similar to that of Sult1C2 and PAPS (Figure 
68).  
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Figure 65: Post-Translational Modification of Mitochondria Respiration by 
SULT1C2. Mitochondria states II and III respiration were analyzed with 500 ng of 
mitochondria in the presence of PAPS, SULT1C2, and SULT1C2/PAPS. (n=4 in all 
groups; * p<0.05 Mitochondria alone versus SULT1C2 and PAPS; $p<0.05 PAPS alone 
versus SULT1C2 and PAPS; # p<0.05 SULT1C2 alone versus SULT1C2 and PAPS. 
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Figure 66: FLIM Analysis of Sult1C2 and PAPS on Mitochondria Membrane Fluidity. 
Mitochondria lysates were analyzed by FLIM following the addition of Laurdan, 
Mitotracker Red, Sult1C2, and PAPS. Phasor plot indicates the addition of SULT1C2 and 
PAPs decrease Laurdan lifetime indicating potential changes in mitochondria membrane 
packaging. 
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Figure 67: Sulfotyrosine Immune Blot. Mitochondria sulfotyrosine levels were analyzed 
in the presence of Sult1C2 alone or with Sult1C2/PAPS. Addition of SULT1C2/PAPS 
decreased the presence of sulfated tyrosine (n=4; *p<0.05 Mitochondria alone versus 
SULT1C2/PAPS). 
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Figure 68: Lipid Sulfation Increases Mitochondria Respiration Similar to Sult1C2. 
Mitochondria respiration analyzed in the presence of cholesterol sulfate. Data indicates 
the addition of the cholesterol sulfate increases mitochondria respiration similar to 
Sult1C2 and PAPS (* p <0.05 Control versus Cholesterol Sulfate; # p <0.05 Control 
versus Sult1C2/PAPS). 
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5.2.4 SULT1C2 Conclusion 
 
The identification of Sult1C2 in our proteomic analysis clearly indicated its 
importance in protecting the kidney from AKI. In addition, we demonstrate for the first 
time that the action of this protein occurs post-translationally (Figure 65). To determine if 
this post-translational modification occurred to proteins we performed an immune blot. 
Our immune blot indicated a decrease in mitochondria membrane protein sulfation 
following the addition of Sult1C2 and PAPS compared to control mitochondria (Figure 
66). The lack of sulfate addition to mitochondria membrane proteins following the 
addition of Sult1C2 and PAPS reduced the likelihood of proteins contributing to the 
membrane and respiration changes (Figure 67). Next, we analyzed if this post-
translational sulfation occurred to cholesterol. Mitochondria state three respiration was 
analyzed in the presence of cholesterol sulfate. Our data indicated that the addition of 
cholesterol sulfate increased mitochondria state three respiration similar to that of 
Sult1C2 and PAPS (Figure 68). Collectively our data indicated that Sult1C2 sulfated 
cholesterol found in the mitochondria membrane. This sulfation reduced membrane 
fluidity leading to potential increases in electron flow through the ETC culminating in 
increased state three respiration.   
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CHAPTER 6: DISCUSSION 
Acute kidney injury is a complex disease to study. Treatment is limited; 
progression to irreversible forms of kidney injury is likely; and mortality rates continue to 
rise despite advances in modern medicine. A common misconception with renal disease 
is that dialysis is the cure. In reality, once a patient is placed on dialysis the likelihood of 
eliminating the need for dialysis is slim and quality of life is poor. Aside from time spent 
in the hospital, cost of renal treatment increases annually while the technology remains 
the same. Our goal was to develop a means to eliminate need for continued dialysis 
treatment and to reduce cost. We believe hydrodynamic fluid delivery through the renal 
vein provides a mechanism for treatment.  
AKI targets the kidney on both a cell and organelle level. On the cellular level, 
AKI targets both the renal epithelium (specifically tubular epithelial cells) and the 
endothelium. Damage to these cell types includes vascular congestion caused by red and 
white blood cell aggregation, necrotic tissue, and mononuclear cell infiltration leading to 
inflammation (9, 19, 20, 42, 43). This damage is associated with poor capillary blood 
flow culminating in decreased filtration and urine output. On an organelle level, AKI 
targets renal mitochondria leading to bioenergetic changes resulting in decreased 
glycolytic and oxidative output. These changes in energetic output cause alterations in 
mitochondria structure and function, activating signaling pathways which initiate cell 
death cascades (165, 166). In order to treat AKI, both aspects of injury must be 
addressed.  
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Treatments for AKI fall into one of two groups. First, we considered patients 
suffering from AKI and aimed to develop a means to reverse disease progression by 
reducing vascular congestion and immune cell infiltration culminating in normal blood 
flow. The second group consists of patients at risk for AKI, but who have not yet 
developed the disease. We used our understanding of ischemic preconditioning (IPC) to 
study proteins responsible for the preconditioned state and proposed potential 
mechanisms for renal gene therapy. The goal for our type of gene delivery is to mimic 
IPC. The commonality between each group was the tool used for treatment. We used 
hydrodynamic fluid delivery of saline or mitochondrial genes to reverse or prevent AKI.  
 Our model of AKI consists of a 35-minute ischemic injury followed by 24 hours 
of reperfusion at which point we analyze our injury with serum creatinine measurements 
and tissue histology (Figures 17 and 19). Following injury, we used hydrodynamic 
isotonic fluid delivery through renal vein or control injections in the vena cava to study 
injury reversal. Following hydrodynamic isotonic fluid delivery, we see reductions in 
SCr, vascular congestion, and medullary tissue injury not seen in control vena cava 
injections (Figure 17, 19, and 20). In addition to these reductions, we also see reductions 
in mononuclear cell infiltration not seen in our control injections (Figures 25-27). Since 
congestion and inflammation are leading causes in reduction of renal blood flow, we 
decided to analyze renal blood flow before and after hydrodynamic isotonic fluid 
delivery. We found that following injury there was an 81% reduction in blood flow 
compared to our control animals. 30 minutes following hydrodynamic isotonic fluid 
delivery we see a two-fold increase in renal blood flow compared to pre-HIFD values 
(Figure 22). A major finding from our blood flow study came when we analyzed Hoechst 
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33342 (nuclear stain) which has a molecular weight of 452 g/mol. This weight is similar 
to medications, such as steroids or ionotropes, currently used for treating kidney injury. 
Following injury, Hoechst 33342 levels were low, indicating potential decreases in 
cellular permeability. However, following hydrodynamic isotonic fluid delivery, there 
was a four-fold increase in fluorescence intensity (Figures 22 and 23). This suggests that 
hydrodynamic isotonic fluid delivery allows movement of compounds through the cell 
membrane regardless of decreased membrane permeability, without damage to the 
epithelium (Figure 25). In Chapter 3 we are able to demonstrate a mechanism by which 
we can ameliorate AKI, by reducing congestion and immune cell infiltration, and propose 
a technique that is translatable to the clinic.  
Despite the ability to reverse AKI, the kidney remains susceptible to future injury 
(Figure 32). Prevention of AKI by IPC was discovered in work by Zager et al (57) and 
Joo et al (58). Zager et al demonstrated that ischemic preconditioning is possible in the 
kidney, and Joo et al demonstrated in murine models that non-lethal doses of ischemia 
can protect the kidney from future IRI. Using this information, we analyzed the proteome 
of rat kidneys that were subjected to IPC. We found 12 potential candidate proteins (six 
upregulated, six downregulated) that promote recovery from injury. We chose to analyze 
Isocitrate Dehydrogenase II (IDH2), a mitochondria protein involved in the TCA cycle 
and reactive oxygen species reduction. Using hydrodynamic delivery, we delivered IDH2 
through the renal vein seven days prior to IRI. Delivery of IDH2 prior to IRI protects the 
kidney from injury, prevents renal cell death, and maintains mitochondria respiration and 
ATP levels (Figures 48-52). Our findings are similar to Han et al, who demonstrate that 
IDH2 knockdown leads to impaired mitochondria and thus disease, stressing the 
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importance of IDH2 in maintaining normal renal function (86). Using this information, 
we next analyzed the potential mechanism of IDH2 protection. Using TMRM and JC-1, 
mitochondrial membrane dyes that are sensitive to changes in membrane potential, we 
found that IDH2 increases membrane potential in a similar fashion to IPC (Figure 37; 
Figures 44-45). This increase in membrane potential is associated with prevention of cell 
death pathways, coupled with increase in mitochondria bioenergetic pathway activity 
(62). Analysis of mitochondria respiration revealed that transfection or delivery of IDH2 
increased states I, II, and III respiration (Figure 38-42; Figure 46). Interestingly, IDH2 
transfection also increased SRC, spare respiratory capacity, which has been linked to 
survival of cells prone to oxidative stress (167-170). IDH2 transfection increases SRC 
indicating that prior to injury onset, cells are primed to handle oxidative stress and 
allocate additional energy to aid in cellular recovery. As we mentioned earlier, IDH2 
generates NAD(P)H which can be used either in the electron transport chain or in the 
oxidation of H2O2. We hypothesized that gene delivery of IDH2 would increase the levels 
of NAD(P)H in the cell. We analyzed the levels of NAD(P)H using FLIM. Our data 
indicates that transfection of IDH2 does not change the levels of NAD(P)H in the cell 
(Figure 48-49). While our hypothesis was not correct, the results were not surprising. A 
major driving force of normal mitochondria metabolism is the separation and 
maintenance of reduction pools. For example, it is critical that cells maintain the proper 
ratio of NAD+ to NADH in the cytoplasm and the mitochondria to promote the 
continuation of glycolysis and the ETC. It is reported that in normal rat liver cytoplasm 
the ratio of NAD+ to NADH 725 and in the mitochondria the ratio is 8 (171). This ratio 
only changes during times of stress or injury when it becomes difficult to maintain 
152 
 
 
homeostasis. Therefore, the absence of increased reduction potential following IDH2 
transfection in a normal cell is not surprising and our data indicates the importance of 
maintaining these ratios. Our final oxidative analysis was of ATP levels following 
delivery of IDH2. We found that delivery of IDH2 increases ATP/AMP ratio (Figure 36 
and Figure 52). This ratio increase corresponds to a potential increase in ATP stores 
providing oxidative capacity needed to recover from IRI. We believe that increases in 
membrane potential, SRC, and ATP indicate prevention of a glycolytic shift typically 
seen following ischemic injuries (172). IDH2 acts to increase metabolic output in 
preparation for injury. It is important to point out that mitochondria biogenesis may also 
be a mechanism by which IDH2 protects against AKI, and is an area of future study. 
Mitochondria biogenesis, like IPC, is regulated by PGC-1 α, and analyzing changes in 
this factor may point to the role of IDH2 in both IPC and mitochondria biogenesis (173). 
We were able to demonstrate a mechanism by which we can ameliorate and 
prevent AKI. The critical aspect of hydrodynamic fluid delivery is that it is practical and 
translatable to the clinic. We believe this tool will one day be used in the clinic not just to 
reverse AKI, but also to prevent its onset. IDH2 and SULT1C2 are only two of the 12 
potential candidate proteins that can be used to mimic IPC. Further studies are needed to 
determine the potential role of these additional candidate proteins in preventing AKI. 
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